<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523419311833</prism:url><dc:identifier>doi:10.1016/j.ejmech.2019.112025</dc:identifier><eid>1-s2.0-S0223523419311833</eid><prism:doi>10.1016/j.ejmech.2019.112025</prism:doi><pii>S0223-5234(19)31183-3</pii><dc:title>Dual-target kinase drug design: Current strategies and future directions in cancer therapy </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>188</prism:volume><prism:startingPage>112025</prism:startingpage><prism:pageRange>112025</prism:pagerange><articleNumber>112025</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-02-15</prism:coverdate><prism:coverDisplayDate>15 February 2020</prism:coverdisplaydate><prism:copyright>Â© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Sun, Dejuan</dc:creator><dc:creator>Zhao, Yuqian</dc:creator><dc:creator>Zhang, Shouyue</dc:creator><dc:creator>Zhang, Lan</dc:creator><dc:creator>Liu, Bo</dc:creator><dc:creator>Ouyang, Liang</dc:creator><dc:description>
                  Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival. The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer. Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis. A series of small-molecule drugs have been approved for the current cancer therapy. However, their complicated inherent mechanisms may lead to the resistance to such small molecules. Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems. In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chemistry strategies and computational approaches. Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Protein kinases</dcterms:subject><dcterms:subject>Cancer therapy</dcterms:subject><dcterms:subject>Dual-target kinase drug design</dcterms:subject><dcterms:subject>Medicinal chemistry design</dcterms:subject><dcterms:subject>Computational drug design</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523419311833" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523419311833" rel="scidir"/></link></coredata><objects><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="155" height="45" size="2791">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="88" height="72" size="1921">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="132" height="56" size="2339">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="126" height="58" size="2848">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="253" size="48326">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="141" height="54" size="2467">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="558" size="58857">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="131" height="70" size="2661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="134" height="85" size="3492">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="44" size="2696">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="389" height="200" size="22309">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="418" size="98232">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="108" height="58" size="2218">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="120" height="104" size="2535">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="56" size="2936">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="138" height="81" size="3200">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="94" height="125" size="3280">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="141" height="37" size="2255">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="127" height="40" size="2044">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="141" height="90" size="3024">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="71" height="60" size="1997">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="142" height="86" size="3017">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="181" height="56" size="3125">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="135" height="74" size="2868">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="132" height="77" size="2873">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="64" size="2146">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="201" height="164" size="3082">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="2531">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="100" size="2604">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="6969">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="83" size="2315">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="196" height="163" size="5181">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="118" size="2513">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="139" size="3321">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="54" size="2715">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="7366">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="137" size="12400">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="118" size="2725">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="164" size="2302">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="69" size="3020">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="2814">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="124" height="164" size="3479">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="1935">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="69" size="2317">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="141" size="2806">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="193" height="164" size="3845">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="132" size="2881">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="68" size="2851">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="119" size="2661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="128" size="2668">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="690" height="202" size="17640">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="392" height="319" size="13431">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="587" height="247" size="18063">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="561" height="257" size="17529">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="1119" size="464100">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="628" height="239" size="17617">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="2470" size="473169">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="582" height="313" size="18519">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="597" height="378" size="24138">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="779" height="193" size="19491">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1724" height="886" size="245120">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="1851" size="853905">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="482" height="260" size="14892">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="464" size="18169">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="779" height="247" size="22782">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="613" height="359" size="22818">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="416" height="551" size="24649">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="628" height="163" size="14862">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="566" height="179" size="15308">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="625" height="401" size="23378">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="317" height="269" size="13538">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="630" height="381" size="23331">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="801" height="248" size="21667">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="600" height="327" size="20148">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="586" height="343" size="19336">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="1996175">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419311833-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85077659712</scopus-id><scopus-eid>2-s2.0-85077659712</scopus-eid><pubmed-id>31931340</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85077659712" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200102">2020-01-02</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200102">2020-01-02</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200110">2020-01-10</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200110">2020-01-10</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-02-25T16:44:30</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523419311833</xocs:eid>
      <xocs:pii-formatted>S0223-5234(19)31183-3</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523419311833</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2019.112025</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.2</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523419X00252</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20201210">2020-12-10T06:59:04.996978Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200215</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1577981570">2020-01-02T16:12:50.534354Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>188</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>188</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 188</xocs:vol-iss-suppl-text>
      <xocs:sort-order>7</xocs:sort-order>
      <xocs:first-fp>112025</xocs:first-fp>
      <xocs:article-number>112025</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112025</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20200215</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 February 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-02-15</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review Papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DUALTARGETKINASEDRUGDESIGNCURRENTSTRATEGIESFUTUREDIRECTIONSINCANCERTHERAPY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>SUN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>D</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Medicinal chemistry design strategies of dual-target kinase drugs in cancer</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Repurposing of dual-target kinase drugs</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Skeleton modification of dual-target kinase drugs</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Pharmacophore-based combination of single-target kinase drugs</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Linked pharmacophore approach</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Fused pharmacophore approach</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Merged pharmacophore approach</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Computational design of dual-target kinase drugs in cancer</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Docking-based drug design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Pharmacophore-based drug design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Fragment-based drug design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>3.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Artificial intelligence (AI)-based drug design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Challenges and future perspectives</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-section-title>Abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>BHULLAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>48</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>COHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-last-lp>315</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>ANASTASSIADIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1039</xocs:ref-first-fp>
            <xocs:ref-last-lp>1045</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>HUGHES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>459</xocs:ref-first-fp>
            <xocs:ref-last-lp>471</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>RUDMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>310</xocs:ref-first-fp>
            <xocs:ref-last-lp>314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>PARVEEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>123</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>COCCO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1422</xocs:ref-first-fp>
            <xocs:ref-last-lp>1427</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>STAUNTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>659</xocs:ref-first-fp>
            <xocs:ref-last-lp>666</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1639</xocs:ref-first-fp>
            <xocs:ref-last-lp>1651</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>PRATILAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4519</xocs:ref-first-fp>
            <xocs:ref-last-lp>4524</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>LAVOIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>549</xocs:ref-first-fp>
            <xocs:ref-last-lp>553</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>SUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>118</xocs:ref-first-fp>
            <xocs:ref-last-lp>122</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>MAEMONDO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2380</xocs:ref-first-fp>
            <xocs:ref-last-lp>2388</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>REDDY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>47</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>SHAH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>118</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>RIBEIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>9</xocs:ref-first-fp>
            <xocs:ref-last-lp>12</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>ROSKOSKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>19</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>INOKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>577</xocs:ref-first-fp>
            <xocs:ref-last-lp>590</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>PLEWS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>748</xocs:ref-first-fp>
            <xocs:ref-last-lp>756</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>MANETTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3278</xocs:ref-first-fp>
            <xocs:ref-last-lp>3286</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>7031</xocs:ref-first-fp>
            <xocs:ref-last-lp>7041</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>ANDRS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>71</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>NACHT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>712</xocs:ref-first-fp>
            <xocs:ref-last-lp>721</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>ZHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4023</xocs:ref-first-fp>
            <xocs:ref-last-lp>4035</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>SILVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>901</xocs:ref-first-fp>
            <xocs:ref-last-lp>905</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>DANIELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>100</xocs:ref-first-fp>
            <xocs:ref-last-lp>114</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>TAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>183</xocs:ref-first-fp>
            <xocs:ref-last-lp>196</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>RIGGS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>8989</xocs:ref-first-fp>
            <xocs:ref-last-lp>9002</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>7785</xocs:ref-first-fp>
            <xocs:ref-last-lp>7795</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>CHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>91</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>ZHAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>4023</xocs:ref-first-fp>
            <xocs:ref-last-lp>4035</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>BARRETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>6501</xocs:ref-first-fp>
            <xocs:ref-last-lp>6504</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>VANDORT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2512</xocs:ref-first-fp>
            <xocs:ref-last-lp>2522</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>125</xocs:ref-first-fp>
            <xocs:ref-last-lp>137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>BOERNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>7059</xocs:ref-first-fp>
            <xocs:ref-last-lp>7071</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>BARCHECHATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>380</xocs:ref-first-fp>
            <xocs:ref-last-lp>387</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>LARROQUELOMBARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>981</xocs:ref-first-fp>
            <xocs:ref-last-lp>991</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>393</xocs:ref-first-fp>
            <xocs:ref-last-lp>403</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>LARROQUELOMBARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>309</xocs:ref-first-fp>
            <xocs:ref-last-lp>318</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>7245</xocs:ref-first-fp>
            <xocs:ref-last-lp>7260</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1230</xocs:ref-first-fp>
            <xocs:ref-last-lp>1241</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>273</xocs:ref-first-fp>
            <xocs:ref-last-lp>289</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>ADAMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1324</xocs:ref-first-fp>
            <xocs:ref-last-lp>1337</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>LABI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1325</xocs:ref-first-fp>
            <xocs:ref-last-lp>1338</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>WENDT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1123</xocs:ref-first-fp>
            <xocs:ref-last-lp>1143</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>TANAKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>9635</xocs:ref-first-fp>
            <xocs:ref-last-lp>9645</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>OCANA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>e95219</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>HAUSCHILD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>358</xocs:ref-first-fp>
            <xocs:ref-last-lp>365</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>SWEETLOVE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>135</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>2445</xocs:ref-first-fp>
            <xocs:ref-last-lp>2455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>997</xocs:ref-first-fp>
            <xocs:ref-last-lp>1011</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>8233</xocs:ref-first-fp>
            <xocs:ref-last-lp>8262</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>HEINRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>297</xocs:ref-first-fp>
            <xocs:ref-last-lp>314</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>739</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>982</xocs:ref-first-fp>
            <xocs:ref-last-lp>996</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>AROOJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>e60470</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>NITISS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>327</xocs:ref-first-fp>
            <xocs:ref-last-lp>337</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>JUN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>453</xocs:ref-first-fp>
            <xocs:ref-last-lp>468</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>358</xocs:ref-first-fp>
            <xocs:ref-last-lp>364</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>MIDUTURU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>868</xocs:ref-first-fp>
            <xocs:ref-last-lp>879</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>DEKLOE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>630</xocs:ref-first-fp>
            <xocs:ref-last-lp>646</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>FRETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>8717</xocs:ref-first-fp>
            <xocs:ref-last-lp>8721</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>HESSLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1191</xocs:ref-first-fp>
            <xocs:ref-last-lp>1204</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>8071</xocs:ref-first-fp>
            <xocs:ref-last-lp>8088</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>45</xocs:ref-first-fp>
            <xocs:ref-last-lp>1560</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>GOMEZBOMBARELLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>268</xocs:ref-first-fp>
            <xocs:ref-last-lp>276</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>PEREIRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2495</xocs:ref-first-fp>
            <xocs:ref-last-lp>2506</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>SUNX2020X112025</xocs:refkey3>
         <xocs:refkey4ai>SUNX2020X112025XD</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-01-10T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-01-10T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">Â© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-01-03T02:33:41.109Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(19)31183-3</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523419311833</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523419311833</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2019.112025</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2020-12-10T06:59:04.996978Z</xocs:timestamp>
         <xocs:cover-date-start>2020-02-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/MAIN/application/pdf/cc3a53550228241a7f8f9693d81e223c/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1679661</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523419311833-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/PREVIEW/image/png/ed786bd5cc8b5a1b87d2ac4259444ed8/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>40830</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx19/DOWNSAMPLED/image/jpeg/93e17fed9429cb4fb141eec94cd8d7ab/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2791</xocs:filesize>
               <xocs:pixel-height>45</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx5/DOWNSAMPLED/image/jpeg/00696499ef447fbf57a7cbdf597cb0ff/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1921</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>88</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx2/DOWNSAMPLED/image/jpeg/ff080aa73022c61fe83fd1c27e71a86e/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2339</xocs:filesize>
               <xocs:pixel-height>56</xocs:pixel-height>
               <xocs:pixel-width>132</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx9/DOWNSAMPLED/image/jpeg/b3bbb2c30d2a05a5213b351b99e98e0c/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2848</xocs:filesize>
               <xocs:pixel-height>58</xocs:pixel-height>
               <xocs:pixel-width>126</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr2/DOWNSAMPLED/image/jpeg/2e62c54604dd75ce10d3e621d0eba789/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>48326</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx3/DOWNSAMPLED/image/jpeg/beb428a0b383b594cf74bf9647e14ded/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2467</xocs:filesize>
               <xocs:pixel-height>54</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr1/DOWNSAMPLED/image/jpeg/a410205c18906834cf9ef7e775fb2d07/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58857</xocs:filesize>
               <xocs:pixel-height>558</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx20/DOWNSAMPLED/image/jpeg/fc05fbe756b76906561a9e9078eb253a/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2661</xocs:filesize>
               <xocs:pixel-height>70</xocs:pixel-height>
               <xocs:pixel-width>131</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx8/DOWNSAMPLED/image/jpeg/2f4c730e5d036c5eb226fdbd9c78c455/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3492</xocs:filesize>
               <xocs:pixel-height>85</xocs:pixel-height>
               <xocs:pixel-width>134</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx14/DOWNSAMPLED/image/jpeg/dd49f2323904ec820cd654471f4e7627/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2696</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx1/DOWNSAMPLED/image/jpeg/74a8b45dcc77f0296d2fee2e684fc25c/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22309</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>389</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr3/DOWNSAMPLED/image/jpeg/054660d8a8bcb0819800519e80341f58/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>98232</xocs:filesize>
               <xocs:pixel-height>418</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx18/DOWNSAMPLED/image/jpeg/e79f6817ad45d01fea783eea687385d8/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2218</xocs:filesize>
               <xocs:pixel-height>58</xocs:pixel-height>
               <xocs:pixel-width>108</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx4/DOWNSAMPLED/image/jpeg/a756123c7658d927685c808258c72074/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2535</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>120</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx13/DOWNSAMPLED/image/jpeg/786750a0e9fd4b4637a156873ba9275e/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2936</xocs:filesize>
               <xocs:pixel-height>56</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx15/DOWNSAMPLED/image/jpeg/6d64a4c836ab5db0b627a7cccbccbfd5/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3200</xocs:filesize>
               <xocs:pixel-height>81</xocs:pixel-height>
               <xocs:pixel-width>138</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx17/DOWNSAMPLED/image/jpeg/e4fc5ceb1bba2a690a813bec38540c13/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3280</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>94</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx16/DOWNSAMPLED/image/jpeg/5781b7e86b94b54f2292a90fd9d64785/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2255</xocs:filesize>
               <xocs:pixel-height>37</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx21/DOWNSAMPLED/image/jpeg/b71cb608325acf9c199fbae2ddc24d46/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2044</xocs:filesize>
               <xocs:pixel-height>40</xocs:pixel-height>
               <xocs:pixel-width>127</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx12/DOWNSAMPLED/image/jpeg/1419599e107aa47414418d6d479e99c9/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3024</xocs:filesize>
               <xocs:pixel-height>90</xocs:pixel-height>
               <xocs:pixel-width>141</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx10/DOWNSAMPLED/image/jpeg/935fc20b6fc50ad9d25b8ba7a8401b09/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1997</xocs:filesize>
               <xocs:pixel-height>60</xocs:pixel-height>
               <xocs:pixel-width>71</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx6/DOWNSAMPLED/image/jpeg/a2996371f0cd02c5b773ebe531878601/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3017</xocs:filesize>
               <xocs:pixel-height>86</xocs:pixel-height>
               <xocs:pixel-width>142</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx11/DOWNSAMPLED/image/jpeg/313b43efb578bb88d0a774fba0fad1e5/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3125</xocs:filesize>
               <xocs:pixel-height>56</xocs:pixel-height>
               <xocs:pixel-width>181</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx22/DOWNSAMPLED/image/jpeg/1775abd7db698cd533d52d50fd85966f/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2868</xocs:filesize>
               <xocs:pixel-height>74</xocs:pixel-height>
               <xocs:pixel-width>135</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx7/DOWNSAMPLED/image/jpeg/f1f6716d4a4d1a44ec07a2d1e4a16fed/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2873</xocs:filesize>
               <xocs:pixel-height>77</xocs:pixel-height>
               <xocs:pixel-width>132</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx19/THUMBNAIL/image/gif/af510d31a23b42a937b4f9f9ede46f40/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2146</xocs:filesize>
               <xocs:pixel-height>64</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx5/THUMBNAIL/image/gif/8665416243a2957215e5be9afb1d48d7/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3082</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>201</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx2/THUMBNAIL/image/gif/80c5185c9951e4a294aa7fc6ff936f0d/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2531</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx9/THUMBNAIL/image/gif/4e739ca6e63a9d736e17d98d10cc2e1e/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2604</xocs:filesize>
               <xocs:pixel-height>100</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr2/THUMBNAIL/image/gif/65f12160564b6bf0134dbecbbb3f4aea/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6969</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx3/THUMBNAIL/image/gif/9f53310b6146ad3129c6c07f442d000a/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2315</xocs:filesize>
               <xocs:pixel-height>83</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr1/THUMBNAIL/image/gif/a9bc76ca9e3eca8d1bbd37f3af392a1d/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5181</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>196</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx20/THUMBNAIL/image/gif/8442633b1ab8265b2f06d2997fe211ea/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2513</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx8/THUMBNAIL/image/gif/cadfc4112ece37e8d9ebf5e942a6990f/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3321</xocs:filesize>
               <xocs:pixel-height>139</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx14/THUMBNAIL/image/gif/8d9ac863b95233a17cbe68a2475a49a3/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2715</xocs:filesize>
               <xocs:pixel-height>54</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx1/THUMBNAIL/image/gif/f69d54c8cbd5ee8b1055682a35c62486/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7366</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr3/THUMBNAIL/image/gif/3deebba5ee64b24a73625ce7ec0356b5/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12400</xocs:filesize>
               <xocs:pixel-height>137</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx18/THUMBNAIL/image/gif/ad2ffeb4aba5d5c0efd8b3467921ef67/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2725</xocs:filesize>
               <xocs:pixel-height>118</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx4/THUMBNAIL/image/gif/8b6e1b0fef1b2864c38b71c303f81cf7/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2302</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx13/THUMBNAIL/image/gif/fe8a64352d31d8c808f3d07e1793773b/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3020</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx15/THUMBNAIL/image/gif/3b1022f349ee3f3586ee62dbd7502df9/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2814</xocs:filesize>
               <xocs:pixel-height>128</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx17/THUMBNAIL/image/gif/c67a58399a8be5e030e3618ac681cee0/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3479</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>124</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx16/THUMBNAIL/image/gif/d8b5c9560b1a8424fadb9ce4ffd5184f/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1935</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx21/THUMBNAIL/image/gif/0413205bdb21c02c4580cd0b79fa2928/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2317</xocs:filesize>
               <xocs:pixel-height>69</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx12/THUMBNAIL/image/gif/287925e8040d47e2d1cb44c333154c4a/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2806</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx10/THUMBNAIL/image/gif/0d0ce6af1c9ae713e95136d188a558bb/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3845</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx6/THUMBNAIL/image/gif/3a128c4fdb210402382e9fe4634ea6e9/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2881</xocs:filesize>
               <xocs:pixel-height>132</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx11/THUMBNAIL/image/gif/4284f22a32462d6597782a317a4810b7/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2851</xocs:filesize>
               <xocs:pixel-height>68</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx22/THUMBNAIL/image/gif/7c71a96bc8e3e0f123d906c9a7a328f5/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2661</xocs:filesize>
               <xocs:pixel-height>119</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx7/THUMBNAIL/image/gif/9fa163ec7593c6291b2d83fa35eb2859/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2668</xocs:filesize>
               <xocs:pixel-height>128</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx19/HIGHRES/image/jpeg/d072dc58e0997f29a42f1021daea3e1e/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17640</xocs:filesize>
               <xocs:pixel-height>202</xocs:pixel-height>
               <xocs:pixel-width>690</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx5/HIGHRES/image/jpeg/daf4790732415d0a10079f7af44d7e09/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13431</xocs:filesize>
               <xocs:pixel-height>319</xocs:pixel-height>
               <xocs:pixel-width>392</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx2/HIGHRES/image/jpeg/e83272c015c7826258c20b853e513574/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18063</xocs:filesize>
               <xocs:pixel-height>247</xocs:pixel-height>
               <xocs:pixel-width>587</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx9/HIGHRES/image/jpeg/5c4029040cadb9171ddb964d6ecaa24c/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17529</xocs:filesize>
               <xocs:pixel-height>257</xocs:pixel-height>
               <xocs:pixel-width>561</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr2/HIGHRES/image/jpeg/34529f2d3ddf2261f17b0cd760633d4b/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>464100</xocs:filesize>
               <xocs:pixel-height>1119</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx3/HIGHRES/image/jpeg/46e7b39a983a91d1952acb002e7fe9b2/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>17617</xocs:filesize>
               <xocs:pixel-height>239</xocs:pixel-height>
               <xocs:pixel-width>628</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr1/HIGHRES/image/jpeg/8c84975c9b7f2adca7631e7eba4765e4/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>473169</xocs:filesize>
               <xocs:pixel-height>2470</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx20/HIGHRES/image/jpeg/1386b6fbee351138ae7904947badf703/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18519</xocs:filesize>
               <xocs:pixel-height>313</xocs:pixel-height>
               <xocs:pixel-width>582</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx8/HIGHRES/image/jpeg/4ccdef398d8889ee3760be7c13ddb547/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24138</xocs:filesize>
               <xocs:pixel-height>378</xocs:pixel-height>
               <xocs:pixel-width>597</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx14/HIGHRES/image/jpeg/6851c5ef53a94defff75b7fab126775c/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19491</xocs:filesize>
               <xocs:pixel-height>193</xocs:pixel-height>
               <xocs:pixel-width>779</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx1/HIGHRES/image/jpeg/6a523e3be469b96e05f3c4896d0c9af8/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>245120</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1724</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/gr3/HIGHRES/image/jpeg/b1e7f5749f1aea70584030563372eba0/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>853905</xocs:filesize>
               <xocs:pixel-height>1851</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx18/HIGHRES/image/jpeg/e3cebf5730faa0edc2a5437ae4c4db0f/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14892</xocs:filesize>
               <xocs:pixel-height>260</xocs:pixel-height>
               <xocs:pixel-width>482</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx4/HIGHRES/image/jpeg/8d76d8bad6743b46ea4bac4c3c908cf4/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18169</xocs:filesize>
               <xocs:pixel-height>464</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx13/HIGHRES/image/jpeg/af38f58c144364e3e2421533c068f991/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22782</xocs:filesize>
               <xocs:pixel-height>247</xocs:pixel-height>
               <xocs:pixel-width>779</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx15/HIGHRES/image/jpeg/6e4370244c26ac3f797818e686c6503f/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22818</xocs:filesize>
               <xocs:pixel-height>359</xocs:pixel-height>
               <xocs:pixel-width>613</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx17/HIGHRES/image/jpeg/084f0b7ec0e378f7736af71ada8a9438/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>24649</xocs:filesize>
               <xocs:pixel-height>551</xocs:pixel-height>
               <xocs:pixel-width>416</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx16/HIGHRES/image/jpeg/4d62802a567b53b23cd40b81ebff2953/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14862</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>628</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx21/HIGHRES/image/jpeg/706aa6c405e6ace753c2cf3c4f35d96f/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>15308</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>566</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx12/HIGHRES/image/jpeg/3e0049c880a7c4a3765febd2b4bd69db/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23378</xocs:filesize>
               <xocs:pixel-height>401</xocs:pixel-height>
               <xocs:pixel-width>625</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx10/HIGHRES/image/jpeg/a09e43ba43cc88d91fb8324a8ff194bf/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>13538</xocs:filesize>
               <xocs:pixel-height>269</xocs:pixel-height>
               <xocs:pixel-width>317</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx6/HIGHRES/image/jpeg/64a4aed11465a6bdf3522db2cacbe033/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23331</xocs:filesize>
               <xocs:pixel-height>381</xocs:pixel-height>
               <xocs:pixel-width>630</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx11/HIGHRES/image/jpeg/60e74ef74e7772459b6a58ef00749ad1/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>21667</xocs:filesize>
               <xocs:pixel-height>248</xocs:pixel-height>
               <xocs:pixel-width>801</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx22/HIGHRES/image/jpeg/a05c6c5722f95b507c2f4292ae6a5dde/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20148</xocs:filesize>
               <xocs:pixel-height>327</xocs:pixel-height>
               <xocs:pixel-width>600</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523419311833/fx7/HIGHRES/image/jpeg/1bd18b0c45d3569893fd550f86847d23/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>19336</xocs:filesize>
               <xocs:pixel-height>343</xocs:pixel-height>
               <xocs:pixel-width>586</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419311833-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>1996175</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10PQ6LTZP1S/MAIN/application/pdf/dbd92a6a09ce83f3efe0aa94a37fda06/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112025</aid>
            <ce:article-number>112025</ce:article-number>
            <ce:pii>S0223-5234(19)31183-3</ce:pii>
            <ce:doi>10.1016/j.ejmech.2019.112025</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig.Â 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">
                     <ce:bold>Medicinal chemistry (pharmacophore-based) strategies of dual-target kinase drug design.</ce:bold> (A) A dual-target inhibitor of PI3K and MEK identified by the linked pharmacophore approach. (B) A dual-target inhibitor of Mcl-1 and Bcl-xL identified by the fused pharmacophore approach. (C) A dual-target inhibitor of PI3K and BRAF identified by the merged pharmacophore approach.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0015" role="short">Fig.Â 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523419311833/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig.Â 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">
                     <ce:bold>Computational design methods of dual-target kinase drug design.</ce:bold> (A) The workflow for docking-based drug design (Circles of different colors represent compounds with different skeletons). (B) The workflow for pharmacophore-based drug design. (C) The strategy of fragment-based drug design. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig.Â 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523419311833/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig.Â 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">
                     <ce:bold>The pros and cons of dual-target kinase drug design approach</ce:bold>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig.Â 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523419311833/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>TableÂ 1</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="tspara0010" view="all">The representative dual-target kinase drugs for current cancer therapy.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">TableÂ 1</ce:alt-text>
               <tgroup cols="11">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <colspec colname="col7" colnum="7"/></colspec>
                  <colspec colname="col8" colnum="8"/></colspec>
                  <colspec colname="col9" colnum="9"/></colspec>
                  <colspec colname="col10" colnum="10"/></colspec>
                  <colspec colname="col11" colnum="11"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Compound in the original article</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Name</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Structure</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">The type of inhibitors</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Targets</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Strategy</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cell activity</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Enzymatic inhibition assays</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Reference</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OSU-53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(Z)-N-(4-((3-((1-methylcyclohexyl)methyl)-2,4-dioxothiazolidin-5-ylidene)methyl)phenyl)-4-nitro-3-(trifluoromethyl)benzenesulfonamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx2" xlink:href="pii:S0223523419311833/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0035" role="short">Image 2</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AMPK/mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Drug repurposig</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C643 (GI<inf loc="post">50</inf>Â =Â 4.51Â Î¼M), U-Hth-7 (GI<inf loc="post">50</inf>Â =Â 1.63Â Î¼M), SW1736 (GI<inf loc="post">50</inf>Â =Â 4.21Â Î¼M), Hth-104 (GI<inf loc="post">50</inf>Â =Â 3.37Â Î¼M), BCPAP (GI<inf loc="post">50</inf>Â =Â 3,79Â Î¼M), FTC133 (GI<inf loc="post">50</inf>Â =Â 5.90Â Î¼M), TPC1 (GI<inf loc="post">50</inf>Â =Â 7.26Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mTOR (IC<inf loc="post">50</inf>Â =Â 8.23Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">thyroid cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">19</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>2</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BMS-35482513</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523419311833/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0040" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Src (ATP competitive), Abl (ATP noncompetitive)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Src/Abl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Drug repurposig</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>3</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">UNC 2025</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(1r,4r)-4-(2-(butylamino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo [2,3-d]pyrimidin-7-yl)cyclohexan-1-ol</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523419311833/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0045" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ATP competitive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MER/FLT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Drug repurposig</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MER (IC<inf loc="post">50</inf>Â =Â 0.74Â nM), FLT3 (IC<inf loc="post">50</inf>Â =Â 0.80Â nM),</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">acute myelogenous leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 14Â°</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(2S,6R)-2,6-dimethyl-4-(4-morpholino-6-(1H-pyrazol-5-yl)thieno [3,2-d]pyrimidin-2-yl)morpholine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523419311833/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0050" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K/mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">U87MG (IC<inf loc="post">50</inf>Â =Â 0.43Â Î¼M), LNCaP (IC<inf loc="post">50</inf>Â =Â 0.21Â Î¼M), PC-3 (IC<inf loc="post">50</inf>Â =Â 0.446Â Î¼M), SKOV-3 (IC<inf loc="post">50</inf>Â =Â 0.504Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K (IC<inf loc="post">50</inf>Â =Â 15Â nM), mTOR (IC<inf loc="post">50</inf>Â =Â 16Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Glioblastoma; prostate cancer; prostate cancer; ovarian cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SA 16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(R,Z)-N-(2-((3-((1H-imidazole-5-yl)methylene)-2-oxoindolin-5-yl)amino)-2-oxo-1-phenylethyl)-1-(3,4-difluorobenzyl)-2-oxo-1,2-dihydropyridine-3-carboxamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523419311833/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0055" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDK1/Aurora Kinase A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Glioma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(E)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(4-methoxy-1H-pyrrolo [2,3-b]pyridin-5-yl)vinyl)-4-methylbenzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523419311833/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0060" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TAK1/MAP4K2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TAK1 (IC<inf loc="post">50</inf>Â =Â 41Â nM), MAP4K2 (IC<inf loc="post">50</inf>Â =Â 98Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">27</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-((4-(cyclopentyloxy)-5-(2-methylbenzo[<italic>d</italic>]oxazol-6-yl)-7H-pyrrolo [2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523419311833/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0065" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TTK/CLK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cal-51 (IC<inf loc="post">50</inf>Â =Â 0.06Â Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TTK (IC<inf loc="post">50</inf>Â =Â 0005.Î¼M), CLK2 (IC<inf loc="post">50</inf>Â =Â 0.003Â Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3-(cyclopenta-2,4-dien-1-yl)-4-(((7S)-8-cyclopentyl-5,7-dimethyl-6-oxo-5,6,7,8-tetrahydroquinazolin-2-yl)amino)-N-(1-methylpiperidin-4-yl)benzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523419311833/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0070" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ATP competitive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-BD1/PLK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-BD1 (IC<inf loc="post">50</inf>Â =Â 28Â nM), PLK1 (IC<inf loc="post">50</inf>Â =Â 40Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PF-04979064</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(S)-1-(1-(2-hydroxypropanoyl)piperidin-4-yl)-3-methyl-8-(6-methylpyridin-3-yl)-1,3-dihydro-2H-imidazo[ [4,5-c]][ [1,5]]naphthyridin-2-one</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523419311833/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0075" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ATP competitive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K/mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Skeleton modification</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BT20Â cell (IC<inf loc="post">50</inf>Â =Â 9.1Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K (KiÂ =Â 0.13Â nM), mTOR (KiÂ =Â 1.42Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">N-(2-(2-(2-(2-(4-(4-(2-(difluoromethyl)-1H-benzo[<italic>d</italic>]imidazole-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523419311833/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K (I)<br/></br>MEK1(III)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K/MEK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-linked approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A549 (10Â Î¼MÂ <Â IC<inf loc="post">50</inf>Â <Â 25Â Î¼M), D54 (5Â Î¼MÂ <Â IC<inf loc="post">50</inf>Â <Â 10Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MEK1 (0.015Â nMÂ <Â IC<inf loc="post">50</inf>Â <Â 56.7Â nM), PI3K (54Â nMÂ <Â IC<inf loc="post">50</inf>Â <Â 341Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Glioma and lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">33</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SB163</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4-(((2-((2-(4-amino-3-(4-chlorophenyl)-1H-pyrazolo [3,4-d]pyrimidin-1-yl)ethyl)(methyl)amino)ethyl)(methyl)amino)methyl)-N-(4-((3-chlorophenyl)amino)quinazolin-6-yl)benzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523419311833/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR/Src</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-linked approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR (IC<inf loc="post">50</inf>Â =Â 0.32 lM), Src (IC<inf loc="post">50</inf>Â =Â 2.9 lM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AL622</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-((4-((4-((3-chlorophenyl)amino)quinazolin-6-yl)carbamoyl)benzyl)(methyl)amino)ethyl 6-((1-(<italic>tert</italic>-butyl)-3-(4-chlorophenyl)-1H-pyrazolo [3,4-d]pyrimidin-4-yl)carbamoyl)nicotinate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523419311833/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR/Src</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-linked approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4T1 (IC<inf loc="post">50</inf>Â =Â 5.603Â Â±Â 0.820Â Î¼M), MDA-MB 231 (IC<inf loc="post">50</inf>Â =Â 7.338Â Â±Â 0.408Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR (IC<inf loc="post">50</inf>Â =Â 0.610Â Â±Â 0.295Â Î¼M) Src (IC<inf loc="post">50</inf>Â =Â 1.099Â Â±Â 0.072Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">35</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AL414</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(E)-2-(((2-((2-(3-(4-((3-chlorophenyl)amino)quinazolin-7-yl)triaz-2-en-1-yl)ethyl)(methyl)amino)ethyl)carbamoyl)oxy)ethyl (2-methoxy-6-(4-oxo-4H-chromen-2-yl)phenyl)carbamate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S0223523419311833/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR/MEK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-linked approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">DU145 (IC<inf loc="post">50</inf>Â =Â 11.33 lM), MES-SA (IC<inf loc="post">50</inf>Â =Â 24.47 lM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">EGFR (IC<inf loc="post">50</inf>Â =Â 0.102Â Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Prostate breast and uterine sarcoma cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">39</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 14d</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6-(4-(2-(4-(<italic>tert</italic>-butyl)-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-1-yl)-N-hydroxyhexanamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523419311833/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2/HDAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-linked approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HCT116 (IC<inf loc="post">50</inf>Â =Â 9.97Â Î¼M)<br/></br>A549 (IC<inf loc="post">50</inf>Â =Â 9.58Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDM2 (K<inf loc="post">i</inf>Â =Â 0.14Â Î¼M)<br/></br>HDAC1 (IC<inf loc="post">50</inf>Â =Â 0.91Â Î¼M)<br/></br>HDAC6 (IC<inf loc="post">50</inf>Â =Â 17.5Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon cancer and lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">N-(4-methyl-3-((1-(6-methylnICæ¿æ¢ä¸æ otinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523419311833/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ABL/KIT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-fused approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">K562 (GI<inf loc="post">50</inf>Â =Â 27Â nM), GIST-T1 (GI<inf loc="post">50</inf>Â =Â 23Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ABL (IC<inf loc="post">50</inf>Â =Â 46Â nM), c-KIT (IC<inf loc="post">50</inf>Â =Â 75Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CML AND GISTs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(S)-7-(4-(((4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenyl)sulfonyl)carbamoyl)-2,6-dimethylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)pyrazolo [1,5-a]pyridine-2-carboxylic acid</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523419311833/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mcl-1/Bcl-xL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-fused approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Mcl-1 (IC50Â =Â 0.088Â Î¼M), Bcl-XL (IC<inf loc="post">50</inf>Â =Â 0.0037Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">46</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">A7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(4-((4-(2-aminopyrimidin-5-yl)-6-morpholino-1,3,5-triazin-2-yl)(methyl)amino)piperidin-1-yl)(phenyl)methanone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S0223523419311833/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K/BRAF</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-merged approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HCT116 (IC<inf loc="post">50</inf>Â =Â 0.11Â Â±Â 0.01Â Î¼M), A375 (IC<inf loc="post">50</inf>Â =Â 0.10Â Â±Â 0.01Â Î¼M), MCF-7 (IC<inf loc="post">50</inf>Â =Â 0.50Â Â±Â 0.09Â Î¼M), Colo205 (IC<inf loc="post">50</inf>Â =Â 0.09Â Â±Â 0.01Â Î¼M), A549 (IC<inf loc="post">50</inf>Â =Â 0.09Â Â±Â 0.02Â Î¼M) and LOVO (IC<inf loc="post">50</inf>Â =Â 0.08Â Â±Â 0.02Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PI3K-a(IC<inf loc="post">50</inf>Â =Â 15.1Â nM)<br/></br>BRAF<sup loc="post">V600E</sup>(IC<inf loc="post">50</inf>Â =Â 118Â nM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Colon cancer; malignant melanoma; breast cancer; lung cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 9a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1-(5-(<italic>tert</italic>-butyl)isoxazol-3-yl)-3-(3-fluoro-4-((6-(methylamino)pyrimidin-4-yl)oxy)phenyl)urea</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:href="pii:S0223523419311833/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 19</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">I/II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Raf1/ERK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-merged approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MCF-7(IC<inf loc="post">50</inf>Â =Â 0.56Â Â Î¼M)<br/></br>MDA-MB-231 (IC<inf loc="post">50</inf>Â =Â 3.79Â Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Raf1 (IC<inf loc="post">50</inf>Â =Â 0.053Â Î¼M)<br/></br>ERK (IC<inf loc="post">50</inf>Â =Â 1.62Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">51</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound 51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(E)-7-(6,11-dioxa-3-aza-2(4,2)-pyrimidina-1,4(1,3)-dibenzenacyclododecaphan-8-en-44-yloxy)-N-hydroxyheptanamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S0223523419311833/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2/HDAC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pharmacophore-merged approach</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MDA-MB-231 (IC<inf loc="post">50</inf>Â =Â 1.43Â Â Î¼M), HCT-116 (IC<inf loc="post">50</inf>Â =Â 2.23Â Â Î¼M), PC-3 (IC<inf loc="post">50</inf>Â =Â 1.7Â Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2 (IC<inf loc="post">50</inf>Â =Â 1.4Â Î¼M)<br/></br>HDAC6 (IC<inf loc="post">50</inf>Â =Â 2.1Â Î¼M)<br/></br>HDAC2 (IC<inf loc="post">50</inf>Â =Â 49Â Â Î¼M)<br/></br>HDAC10 (IC<inf loc="post">50</inf>Â =Â 80Â Î¼M)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Breast cancer; colorectal cancer; prostate cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">52</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pz-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2-(4-(5-(thiophen-3-yl)-1H-benzo[<italic>d</italic>]imidazole-1-yl)phenyl)-N-(3-(trifluoromethyl)phenyl)acetamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S0223523419311833/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">II</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET<br/></br>VEGFR2<br/></br>RET<sup loc="post">V804M</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Fragment-based drug design</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET (IC<inf loc="post">50</inf>Â <Â 0.001Â Î¼M), VEGFR2 (IC<inf loc="post">50</inf>Â <Â 0.001Â Î¼M), RET<sup loc="post">V804M</sup> (IC<inf loc="post">50</inf>Â <Â 0.001Â Î¼M),</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">62</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BL-AD008</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">(Z)-5-(2-(4-(benzo[<italic>d</italic>]isothiazol-3-yl)piperazin-1-yl)ethyl)-3-benzylidene-6-chloroindolin-2-one</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S0223523419311833/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">â</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AMPK/ZIPK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Machine learning</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">cervical cancer</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">64</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Dual-target kinase drug design: Current strategies and future directions in cancer therapy</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523419311833-bfe105849e9de9132b9e142f15c6f311">
                  <ce:given-name>Dejuan</ce:given-name>
                  <ce:surname>Sun</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523419311833-fba47134f8cdc9ef41a8fbf72cccf17a">
                  <ce:given-name>Yuqian</ce:given-name>
                  <ce:surname>Zhao</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523419311833-743210bd0c4b90d438f8d78e5a410fc4">
                  <ce:given-name>Shouyue</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0035" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523419311833-44e97bd0cf4e24fffd461989a9aa7e39">
                  <ce:given-name>Lan</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0040" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0045" refid="cor2">
                     <ce:sup loc="post">ââ</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au5" author-id="S0223523419311833-71459d87ad4564937ce6ef1350fa7a79">
                  <ce:given-name>Bo</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref id="crosref0050" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0055" refid="cor3">
                     <ce:sup loc="post">âââ</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au6" author-id="S0223523419311833-59b0e80699daa28daf53f417ed3ae89c">
                  <ce:given-name>Liang</ce:given-name>
                  <ce:surname>Ouyang</ce:surname>
                  <ce:cross-ref id="crosref0060" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0065" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523419311833-d94781d9cb5a6797053f5011d540ca21">
                  <ce:label>a</ce:label>
                  <ce:textfn>State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>State Key Laboratory of Biotherapy and Cancer Center</sa:organization>
                     <sa:organization>West China Hospital</sa:organization>
                     <sa:organization>Sichuan University</sa:organization>
                     <sa:organization>Collaborative Innovation Center for Biotherapy</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610041</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523419311833-e3efd840916f33b36e291dab764ebb2b">
                  <ce:label>b</ce:label>
                  <ce:textfn>School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>School of Life Science and Engineering</sa:organization>
                     <sa:organization>Southwest Jiaotong University</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610031</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>ââ</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>âââ</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="24" month="6" year="2019"/></ce:date-received>
            <ce:date-revised day="18" month="12" year="2019"/></ce:date-revised>
            <ce:date-accepted day="29" month="12" year="2019"/></ce:date-accepted>
            <ce:abstract class="author" id="abs0010" xml:lang="en" view="all"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Protein kinases are well-known to orchestrate the activation of signaling cascades in response to extracellular and intracellular stimuli to control cell proliferation and survival. The perturbation of such kinases by some mutation or abnormal protein expressions has been closely linked to cancer. Drug development aimed at several targetable kinases may alter their participated pathways that are able to trigger carcinogenesis. A series of small-molecule drugs have been approved for the current cancer therapy. However, their complicated inherent mechanisms may lead to the resistance to such small molecules. Consequently, development of new dual-target kinase drugs simultaneously aimed at two targetable kinases may improve their anti-tumor efficiency and solve resistant mechanism problems. In this review, we focus on summarizing an overview of the current strategies of dual-target kinase drug design, including medicinal chemistry strategies and computational approaches. Taken together, we believe the above-mentioned strategies will provide a new insight into future directions of dual-target kinase drug design to improve potential cancer therapeutics.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523419311833/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords class="keyword" id="kwrds0010" xml:lang="en" view="all">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Protein kinases</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Cancer therapy</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Dual-target kinase drug design</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Medicinal chemistry design</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Computational drug design</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">Protein kinases have been emerging as a major class of drug targets for pharmacological intervention, as a number of such kinases are implicated in the progression of human cancers [<ce:cross-ref id="crosref0070" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0075" refid="bib2">2</ce:cross-ref>]. Hitherto, to our knowledge, about 50 kinase inhibitors have been approved by the US Food and Drug Administration (FDA), and among them, 45 kinase inhibitors are directed toward the current cancer treatment. Consequently, much effort has been devoted to the development of small-molecule drugs that directly interfere with the catalytic activities of some targetable protein kinases. Despite typically being developed against individual or more targets, small-molecule inhibitors of protein kinases often exhibit considerable cross-reactivities because they are able to target conserved structural elements, such as purine nucleotide-binding pockets of protein kinases [<ce:cross-ref id="crosref0080" refid="bib3">3</ce:cross-ref>]. Recently, treatment with single-target drug has been widely reported to result in the resistance to chemotherapy [<ce:cross-ref id="crosref0085" refid="bib4">4</ce:cross-ref>]. Usually, resistant mechanisms can be classified into two types: âon-targetâ and âoff-targetâ. On one hand, on-target resistance occurs by altering the primary target of a drug, which limits its ability to inhibit the activity of its target. Hurdles of conventional single-target drugs can limit the accessibility of these drugs to tumor tissues [<ce:cross-ref id="crosref0090" refid="bib5">5</ce:cross-ref>]. Subsequently, a higher drug dose should be required, leading to non-specific targeting and intolerable cytotoxicity [<ce:cross-ref id="crosref0095" refid="bib6">6</ce:cross-ref>]. Relatively high epidermal growth factor receptor (EGFR) mutations are observed in lung cancer patients. On the other hand, off-target resistance often occurs when signaling events downstream of or parallel to targeted protein kinases are activated, which favors tumor cell growth and survival. It suggests that off-target resistance in patients treated with TRK inhibitors activates the mitogen-activated protein kinase (MAPK) signaling [<ce:cross-ref id="crosref0100" refid="bib7">7</ce:cross-ref>]. To seek the solution of single-target drug chemotherapeutic cancer treatment, the combination therapy has been recently adopted for clinical uses [<ce:cross-ref id="crosref0105" refid="bib8">8</ce:cross-ref>]. Notably, the combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) has been approved for the treatment of metastatic melanoma with BRAF mutations [<ce:cross-ref id="crosref0110" refid="bib9">9</ce:cross-ref>]. Firstly, tumors with BRAF mutations depend on the extracellular regulated kinase (ERK) signaling pathway for proliferation [<ce:cross-ref id="crosref0115" refid="bib10">10</ce:cross-ref>]. Secondly, MEK can also feedback-activate RAF, cut off this feedback, and thus enhance pathway suppression [<ce:cross-ref id="crosref0120" refid="bib11">11</ce:cross-ref>]. Lastly, long-term use of the RAF inhibitor vemurafenib can lead to oncogene-induced senescence in the RAS-BRAF-MEK signaling pathway, which enhances cellular responses. As mentioned above, patients with this resistance may benefit from synergistic treatment with BRAF-MEK inhibitors [<ce:cross-ref id="crosref0125" refid="bib12">12</ce:cross-ref>]. Moreover, EGFR, a member of the transmembrane receptor tyrosine kinase (RTK) family, is associated with diverse types of cancer. Resistance to tyrosine kinase inhibitors (TKIs) has been reported to frequently occur in EGFR-mutated cancer patients. Consequently, nonâsmall cell lung cancer (NSCLC) patients with mutant EGFR who received erlotinib and gefitinib have been accompanied with dramatic tumor regression [<ce:cross-ref id="crosref0130" refid="bib13">13</ce:cross-ref>]. To address the aforementioned problems, polypharmacology is introduced to treat currently incorrigible diseases and guides developments of compounds with safer, more effective, and affordable medicines. Also, polypharmacology can involve the combinations and/or multitargeted drugs [<ce:cross-ref id="crosref0135" refid="bib14">14</ce:cross-ref>]. More recently, the combination treatment with aurora kinase and EGFR inhibitors has been demonstrated to directly eliminate residual cancer cells without the emergence of genetic resistance [<ce:cross-ref id="crosref0140" refid="bib15">15</ce:cross-ref>]. Under some circumstances, the combination therapy might have an additive and even synergistic effects in theory; however, it often leads to some unpredictable side-effects, such as an increased toxicity. As an alternative strategy for combination therapy, dual-target or multi-target drugs have a lower risk of drug interactions and better pharmacokinetics (PK) and safety profiles. In addition, a dual-target kinase drug could help avoiding the two drug interactions, poor patient compliance, adverse off-target effects and high development costs. There are a number of dual-target or multi-target drugs that have been approved by FDA for anti-cancer treatment. Alectinib (Alecensa, Hoffman-LaRoche) is dual-targeted (ALK and RET) drug for ALK<ce:sup loc="post">+</ce:sup> NSCLC [<ce:cross-ref id="crosref0145" refid="bib16">16</ce:cross-ref>]. Dasatinib (Sprycel, Bristol-Myers Squibb) has nine known targets (BCR-Abl, EGFR, Src, Lck, Yes, Fyn, Kit, EphA2, PDGFR) for CML or ALL. As mentioned above, dual/multi-targeted kinase inhibitors are well adapted to develop potent anti-cancer drugs [<ce:cross-ref id="crosref0150" refid="bib17">17</ce:cross-ref>]. In this review, we provide the current drug design strategies aiming at dual-target kinase, including medicinal chemistry design (e.g., drug repurposing, skeleton modification, and linked/merged/fused pharmacophore), computational design (e.g., docking-, pharmacophore-, fragment-based, and even artificial intelligence (AI)-based design approaches), which would shed new light on the future directions of dual-target kinase drug design for future cancer therapeutics.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Medicinal chemistry design strategies of dual-target kinase drugs in cancer</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">Repurposing of dual-target kinase drugs</ce:section-title>
                     <ce:para id="p0030" view="all">The approved or investigational drug may involve in more than one pathology and modulate the activity of unpredicted targets. Drug repositioning is introduced to explore a new therapeutic area. The cost and time of research would be substantially decreased, because of the prior knowledge of the metabolism and possible side effects. It also has certain limitations. Many successful examples are from large-scale research on drug properties and unexpectedly discovery. It is difficult to translated to general drug repositioning. Otherwise, the structures of the compounds are not novel.</ce:para>
                     <ce:para id="p0035" view="all">A number of small-molecule kinase inhibitors are widely reported to have inherent pharmacophore features and thus they can simultaneously bind to two kinases. For instance, both cyclin-dependent kinase 2 (CDK2) and glycogen synthase kinase 3Î² (GSK3Î²) possess a highly conserved adenosine 5â²-triphosphate (ATP) binding site. In the case of one target binding to a wide range of small-molecule drugs, the recycling of these kinase inhibitors for the other target is the most straightforward method of dual-target drug design [<ce:cross-ref id="crosref0155" refid="bib18">18</ce:cross-ref>]. Moreover, OSU-53 (namely, compound <ce:bold>1</ce:bold>) was a novel dual-target small-molecule of adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in thyroid cancer. Compound <ce:bold>1</ce:bold> could not induce AMPK activation in TPC1 cells, which possess high basal levels of AMPK, but <ce:bold>1</ce:bold> inhibited the growth of BCPAP and FTC133Â cells transfected with siRNA-AMPK. Consequently, it was suggested the dual-target capability of <ce:bold>1</ce:bold> to both activate AMPK and inhibit mTOR, which indicated that <ce:bold>1</ce:bold> was a direct AMPK activator that inhibits cancer cell growth [<ce:cross-ref id="crosref0160" refid="bib19">19</ce:cross-ref>].</ce:para>
                     <ce:para id="p0040" view="all">For better understanding of designing dual-target inhibitors, the types of inhibitors are briefly introduced. Type I inhibitors are kinase inhibitors that target the ATP binding site with DFG-in conformation, while Type II inhibitors bind to protein kinase with the DFG motif is in âoutâ conformation. Type III inhibitors are the allosteric inhibitors that occupy the pocket adjacent to the ATP binding pocket. Type VI inhibitors bind covalently to their protein kinase target. The reported review detailed properties of FDA-approved small molecule protein kinase inhibitors [<ce:cross-ref id="crosref0165" refid="bib17">17</ce:cross-ref>]. The conformations of various inhibitors were clearly shown in the graphical abstract. A dual-target inhibitor of Src (competitive with the ATP substrate) and Abl (noncompetitive inhibitor) has been recently reported. Compound <ce:bold>2</ce:bold>, identified as a Src inhibitor at first, was later described as an Abl inhibitor because of the close homology between Src and Abl. Src and Abl, two non-receptor tyrosine kinases, are mammalian homologs of oncogene products that are associated with complicated cellular functions. Computational pharmacophoric models are applied to identify c-Src tyrosine kinase inhibitors that are in turn applied to find Abl inhibitors, supporting the idea that Src inhibitors can also be used as Abl inhibitors [<ce:cross-ref id="crosref0170" refid="bib20">20</ce:cross-ref>]. Additionally, compound <ce:bold>3</ce:bold>, a potent and orally bioavailable Mer tyrosine kinase inhibitor, had similar subnanomolar activity against Flt3 and was ATP competitive inhibitor. Kinome profiling showed that <ce:bold>3</ce:bold> has excellent kinase inhibitory activity against Flt3, despite differences within their ATP binding sites [<ce:cross-ref id="crosref0175" refid="bib21">21</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">Skeleton modification of dual-target kinase drugs</ce:section-title>
                     <ce:para id="p0045" view="all">Skeleton modification of lead drugs is an effective and common approach to obtain candidate small-molecule drugs. Modifying the skeleton of a compound is usually carried out to improve drug absorption/solubility, reduce toxic side effects and thus enhancing drug specificity. Skeleton modification of lead drugs may be an effective approach to obtain compounds, reduce toxicity and improve metabolic stability and water solubility, but it is only applicable for specific scaffold types of small-molecule compounds.</ce:para>
                     <ce:para id="p0050" view="all">It is reported that the morpholine ring is the most common feature of phosphoinositide 3 kinase (PI3K) inhibitors and may form a critical hydrogen bond with amino acid residues [<ce:cross-ref id="crosref0180" refid="bib22">22</ce:cross-ref>]. Substituents of the thienopyrimidine core and several advanced compounds, such as CNX-1351, was developed from the structure of the PI3K inhibitor pictilisib [<ce:cross-ref id="crosref0185" refid="bib23">23</ce:cross-ref>]. In addition, ZSTK474, another PI3K inhibitor, was designed by incorporating a second morpholine group into the triazine or pyrimidine core to improve solubility or potency. A series of dimorpholine-substituted thienopyrimidine derivatives that potently inhibit the PI3K/AKT/mTOR pathway were prepared, culminating in the discovery of <ce:bold>4</ce:bold> as a dual class I PI3K and mTOR kinase inhibitor [<ce:cross-ref id="crosref0190" refid="bib24">24</ce:cross-ref>]. In addition, OSU-03012 and BX795 were highly hydrophobic PDK1 inhibitors that also exhibited an affinity for AurA. It provided an innovative strategy to design a dual-target PDK1 and AurA inhibitor [<ce:cross-ref id="crosref0195" refid="bib25">25</ce:cross-ref>]. Compound <ce:bold>5</ce:bold> was originally designed as a PDK1 inhibitor by combining two pharmacophoric moieties known to bind the ATP binding site and the allosteric DFG-out pocket of PDK1 through a phenylglycine linker. Compound <ce:bold>5</ce:bold> was highly hydrophobic and significantly inhibits both PDK1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 416Â nM) and AurA (IC<ce:inf loc="post">50</ce:inf>Â =Â 35Â nM), suggesting that this compound was a prototypical dual PDK1/AurA inhibitor [<ce:cross-ref id="crosref0200" refid="bib26">26</ce:cross-ref>]. The remaining examples are summarized in <ce:cross-ref id="crosref0205" refid="tbl1">TableÂ 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor> [<ce:cross-refs id="crosrefs0010" refid="bib27 bib28 bib29 bib30">27â30</ce:cross-refs>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">Pharmacophore-based combination of single-target kinase drugs</ce:section-title>
                     <ce:para id="p0055" view="all">Pharmacophore-based combination of single-target kinase drugs is carried out from the perspective of structural chemistry by considering the common pharmacophores of two inhibitors acting on two kinase targets. Combining distinct pharmacophores from these target kinase inhibitors is conducive to the rational design of a dual- or even multi-target kinase drug with the favorable physicochemical properties. Based upon the similarity of the pharmacophores of the inhibitors on two kinase targets, pharmacophore-based design approaches are classified as follows: linked pharmacophore approach, fused pharmacophore approach, and merged pharmacophore approach (<ce:cross-ref id="crosref0210" refid="fig1">Fig.Â 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>).</ce:para>
                     <ce:section id="sec2.3.1" view="all">
                        <ce:label>2.3.1</ce:label>
                        <ce:section-title id="sectitle0055">Linked pharmacophore approach</ce:section-title>
                        <ce:para id="p0060" view="all">When linker pharmacophore approach is used, a long linker is introduced between two different kinase drugs. Usually, a new drug contains the main structural characteristics of each kinase drug and may be effective against two kinases. When conjugated linkers are used, two distinct pharmacophores are connected through a linker that does not exist in either of the two pharmacophores. The growing amount of structural information of kinases and inhibitors is considered in linker-based drug design. This approach may be useful to assist the rational design of more potent dual-target kinase compounds. Although it still produces some problems involved in metabolism and <ce:italic>inÂ vivo</ce:italic> kinetics, this approach may be useful to aid design of more potent dual-target kinase drugs.</ce:para>
                        <ce:para id="p0065" view="all">N-(2-(2-(2-(2-(4-(4-(2-(difluoromethyl)-1H-benzo[<ce:italic>d</ce:italic>]imidazole-1-yl)-6-morpholino-1,3,5-triazin-2-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethoxy)-3,4-difluoro-2-((2-fluoro-4-iodo phenyl)amino)benzamide was reported to be designed as a MEK and PI3K dual-target inhibitor by linker pharmacophore approach [<ce:cross-ref id="crosref0215" refid="bib31">31</ce:cross-ref>]. The simultaneous inhibition of MEK/PI3K is an attractive approach to completely block two key signaling pathways. Covalently linking the ATP-noncompetitive MEK inhibitor PD0325901 and the ATP-competitive PI3K inhibitor ZSTK474 was a powerful approach used to design a dual-target inhibitor [<ce:cross-ref id="crosref0220" refid="bib32">32</ce:cross-ref>]. One of the morpholine oxygen atoms, the lone pair of the imidazole nitrogen, and the 1,3,5-triazine moiety of ZSTK474 all contributed to strong binding. A piperazine group was easy to synthetically attach to the spacer group bearing the MEK inhibitor. The aromatic ring itself and the iodine moiety also formed hydrophobic interactions within a pocket observed in the crystal structure of MEK. Binding mode of compound <ce:bold>10</ce:bold> was within the MEK1 allosteric site (type III inhibitor). The PI3K portion of compound <ce:bold>10</ce:bold> was out to solvent (type I inhibitor) [<ce:cross-ref id="crosref0225" refid="bib33">33</ce:cross-ref>]. A series of bifunctional MEK/PI3K inhibitors were developed by the linked pharmacophore approach [<ce:cross-ref id="crosref0230" refid="bib34">34</ce:cross-ref>]. Compound <ce:bold>11</ce:bold> was a dual-target inhibitor with a long linker that showed moderate inhibitory activity against Src and good inhibitory activity against EGFR. EGFR and c-Src were expressed during breast cancer cell proliferation and invasion. In breast cancer cells expressing c-Src and EGFR, one of the two oncogenes controlled proliferation and invasion, but in other types of cancer, the synergistic interaction between them was required for tumor progression [<ce:cross-ref id="crosref0235" refid="bib35">35</ce:cross-ref>]. Activation of c-Src in some breast cancer cell lines was reported to lead to the phosphorylation of EGFR at Tyr845 and that the downstream effect was transduced via the STAT 3/5 pathway. A dual-target small molecule had been designed to block both EGFR and Src. Subsequently, this compound containing a quinazoline head (for binding to EGFR) and a 7-phenyl-pyrazolopyrimidine moiety targeting c-Src were designed. The effects of different linkers between the 9-position of pyrazolopyrimidine and the 6-position of quinazoline were investigated [<ce:cross-ref id="crosref0240" refid="bib36">36</ce:cross-ref>]. More recently, a series of dual-target inhibitors of EGFR and c-Src had been reported. For instance, the compound <ce:bold>12</ce:bold> was obtained, wherein a hydrolysable linker was connected to the 6-aminopurine group through an amide bond, which was readily hydrolyzed in the intracellular milieu due to the electron deficiency of the pyridine linker [<ce:cross-ref id="crosref0245" refid="bib37">37</ce:cross-ref>]. The inhibition of aurora kinase A (AurA) and phosphoinositide-dependent kinase-1 (PDK1), each of which plays a crucial role in cellular survival, migration and differentiation, was an attractive strategy to overcome resistance and recurrence in glioblastoma multiforme [<ce:cross-ref id="crosref0250" refid="bib38">38</ce:cross-ref>]. The remaining examples are summarized in <ce:cross-ref id="crosref0255" refid="tbl1">TableÂ 1</ce:cross-ref> [<ce:cross-ref id="crosref0260" refid="bib39">39</ce:cross-ref>,<ce:cross-ref id="crosref0265" refid="bib40">40</ce:cross-ref>].</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.2" view="all">
                        <ce:label>2.3.2</ce:label>
                        <ce:section-title id="sectitle0060">Fused pharmacophore approach</ce:section-title>
                        <ce:para id="p0070" view="all">Conjugated pharmacophoric drugs containing a metabolically cleavable linker are designed to release two drugs with distinct <ce:italic>inÂ vivo</ce:italic> activities. In some cases, to design a smaller and simpler dual-target small molecule, a fused pharmacophore approach is used to maximize the degree of pharmacophore overlap. In this mode, the fusion molecule possesses the respective pharmacophores of small molecules targeting on different kinase. The fusion site should not interfere with the binding of the pharmacophore to the target and can be arranged in a noncritical part of the enzyme or receptor binding cavity. This fused pharmacophore approach allows for the overlap of the active space and ameliorates the pharmacokinetics as well as physicochemical properties of dual-target small molecules.</ce:para>
                        <ce:para id="p0075" view="all">In the canonical DFG-out binding mode, type II kinase inhibitors usually share similar structural features, including a moiety that forms a hydrogen bond at the hinge binding site, a moiety (usually an amide, urea, or 1,3-diketone) that provides two hydrogen bonds with the Glu in the c-helix and the Asp in the DFG motif, and a hydrophobic tail accommodating the hydrophobic pocket formed upon a âDFG-outâ shift [<ce:cross-ref id="crosref0270" refid="bib41">41</ce:cross-ref>]. Recently, a potent type II (DFG-out conformation) ABL/c-KIT dual kinase inhibitor, N-(4-methyl-3-((1-(6-methylnicotinoyl)piperidin-4-yl)oxy)phenyl)-4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)benzamide, had been reported to display a distinct hinge-binding hydrogen bond formed by Glu286 (ABL1)/Glu640 (c-KIT) located in the c-helix and Asp381 (ABL1 and c-KIT) located in the DFG motif. Intriguingly, the compound also adopted a distinct hinge-binding mode in which the amide oxygen serves as the hinge-binding hydrogen-bond donor. It was different from classical hinge binding and may provide the opportunity for new type II inhibitor discovery [<ce:cross-ref id="crosref0275" refid="bib42">42</ce:cross-ref>]. In addition, (S)-7-(4-(((4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenyl)sulfonyl)carbamoyl)-2,6-dimethylphenyl)-3-(3-(naphthalen-1-yloxy)propyl)pyrazolo [1,5-a]pyridine-2-carboxylic acid was designed to interact with both the west and east regions of Mcl-1 and Bcl-xL, respectively. The anti-apoptotic proteins Bcl-xL and Mcl-1 suppressed apoptosis and interact with the pro-apoptotic proteins Bax and Bak that were antagonized by the BH3-only proteins Bad and Noxa [<ce:cross-ref id="crosref0280" refid="bib43">43</ce:cross-ref>,<ce:cross-ref id="crosref0285" refid="bib44">44</ce:cross-ref>]. Although the structures of Bcl-xL and Mcl-1 are similar, their selective properties are different. Inhibiting protein-protein interactions (PPIs) between the anti- and pro-apoptotic proteins would potentially be a therapeutic option in cancer therapy [<ce:cross-ref id="crosref0290" refid="bib45">45</ce:cross-ref>]. Based upon this rationale, hybrid compounds were designed to obtain novel Mcl-1/Bcl-xL dual inhibitors. The first two inhibitors were active against Mcl-1 and Bcl-xL, which contain a few of common chemical groups. Based on X-ray crystallographic analyses of Bcl-xL bound to its inhibitor, the aromatic ring of the inhibitor should have been in the solvent region, which was in the east region of Bcl-xL. Interestingly, the Mcl-1 inhibitor interacts with the west region of Mcl-1, and the benzoic acid group was exposed to the solvent. Consequently, hybrid compounds were designed to obtain novel Mcl-1/Bcl-xL dual inhibitors by connecting the aromatic ring in the Bcl-xL inhibitor and the benzoic acid group in Mcl-1 inhibitor [<ce:cross-ref id="crosref0295" refid="bib46">46</ce:cross-ref>]. Although Mcl-1 and Bcl-xL are not members of the kinase family of enzymes, the design strategy and direction provide good inspiration.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.3" view="all">
                        <ce:label>2.3.3</ce:label>
                        <ce:section-title id="sectitle0065">Merged pharmacophore approach</ce:section-title>
                        <ce:para id="p0080" view="all">The merged pharmacophore strategy requires lead compounds to have the same pharmacophore and share common fragments. Accordingly, the two small molecules are combined and synthesized into one molecule, but their respective pharmacophores remain, producing a smaller and simpler merged small molecule [<ce:cross-ref id="crosref0300" refid="bib47">47</ce:cross-ref>]. Merged pharmacophore is similar to the hybridizing strategy, and it involves the compounds with smaller molecular weight. The merged and fused pharmacophore approaches were developed based on reported small molecules, which limits the diversity of dual target molecules and requires developing new pharmacophores.</ce:para>
                        <ce:para id="p0085" view="all">Compound <ce:bold>17</ce:bold> was a dual-target inhibitor designed by merging the pharmacophores of both VS-5584 (a PI3K inhibitor) and RAF709 (a BRAF inhibitor) [<ce:cross-ref id="crosref0305" refid="bib48">48</ce:cross-ref>]. In addition, PI3K inhibitors had been reported to synergize with BRAF inhibitors to prevent the growth of BRAF mutant cancer cells [<ce:cross-ref id="crosref0310" refid="bib49">49</ce:cross-ref>]. VS-5584 and RAF709 were chosen for the design of PI3K and BRAF dual-target inhibitors. The core pharmacophores of VS-5584 were a morpholine moiety and a 2-aminopyrimidine moiety. The oxygen atom of morpholine generated an H-bond with the hinge region of PI3KÎ±. On the other side of the compound, the oxygen atom in the morpholine ring of RAF709 made an H-bond with residue Cys532 in the BRAF kinase hinge region. The imidazole ring of VS-5584 was modified and synthesized 2,4,6-trisubstituted 1,3,5-triazine. Otherwise, the 1-benzoylpiperidin-4-yl amino moiety met the pharmacophore of the BRAF inhibitor [<ce:cross-ref id="crosref0315" refid="bib50">50</ce:cross-ref>]. This merged pharmacophore approach strongly supported the design of compounds that served as potent dual inhibitors that maintained effective anticancer activity. Moreover, compound <ce:bold>18</ce:bold>, a Raf1 and ERK1 dual-target inhibitor, was designed by a merged strategy. The sequence similarity of Raf1 and ERK1 was approximately 48%, except for additional loops in Raf1 that were not adjacent to the inhibitor binding sites. Otherwise, Raf1 and ERK1 possessed similar binding modes with their respective inhibitors. Thus, a series of compounds were synthesized from the merged pharmacophores of sorafenib (a pan-Raf inhibitor) and BL-EI001 (an ERK inhibitor described in previous studies) [<ce:cross-ref id="crosref0320" refid="bib51">51</ce:cross-ref>]. The design strategy is also adapted to kinase target and non-kinase target. The dual-target inhibitor of JAK2/histone deacetylase (HDAC) was also designed by merged pharmacophore strategy [<ce:cross-ref id="crosref0325" refid="bib52">52</ce:cross-ref>].</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0070">Computational design of dual-target kinase drugs in cancer</ce:section-title>
                  <ce:para id="p0090" view="all">Computational design is another effective method to design novel dual-target drugs, especially for new kinase targets with not reported drugs. Recently, some kinase inhibitors have attracted increasing attention due to the structural diversity of these single-target inhibitors and the limitation of their target combinations. Some inhibitors are designed based upon kinase structures, and multi-target compounds are designed by the involvement of pharmacochemistry, proteomics, and computational chemistry. The dual-target drug design process includes the selection of target combinations and the virtual screening of multi-target small molecules by applying techniques such as data mining, structure analysis, and pharmacophore construction. The small-molecule compounds derived from some virtual compound libraries are structurally diverse. Thus, computational design strategies for dual-target kinase inhibitors in cancer are summarized as follows: multiple docking, the use of common pharmacophores, and fragment-based design (<ce:cross-ref id="crosref0330" refid="fig2">Fig.Â 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>).</ce:para>
                  <ce:section id="sec3.1" view="all">
                     <ce:label>3.1</ce:label>
                     <ce:section-title id="sectitle0075">Docking-based drug design</ce:section-title>
                     <ce:para id="p0095" view="all">A multiple docking approach evaluates the complementarity of a library of small-molecule compounds with the binding sites in the two targets, and potential compounds with the best docking scores are selected for further structural optimization. The molecular docking approach cannot give very reliable predictions, because similar binding pockets exist in kinases. At the current stage, inverse docking approaches suffer from including meager performance of scoring algorithms and difficulty of addressing target flexibility. Otherwise, improving the accuracy and false-positive rate for target selectivity prediction remains a challenge.</ce:para>
                     <ce:para id="p0100" view="all">As opposed to a pharmacophore-based combination strategy, multiple docking may filter out a dual-target drug with a novel framework. For instance, Janus kinases are non-receptor protein tyrosine kinases that mediate signaling in various cytokine pathways, and the anomalous regulation of these pathways often results in various types of cancer [<ce:cross-ref id="crosref0335" refid="bib53">53</ce:cross-ref>]. New dual-target inhibitors of Janus Kinase 2 (JAK2) and JAK3 have been reported by a combination of pharmacophore-based and structure-based virtual screening. First, the high-performance program for ligand-based drug design was used to generate pharmacophore models of JAK2 and JAK3, which were mapped over their corresponding most active molecules [<ce:cross-ref id="crosref0340" refid="bib54">54</ce:cross-ref>]. Afterwards, small molecules in the database were screened with the validated JAK2 pharmacophore model, and some compounds were retrieved. These compounds were subsequently screened by the JAK3 model, and eventually 436 compounds were retrieved. To filter these compounds with poor pharmacokinetic profiles, their ADME properties were calculated [<ce:cross-ref id="crosref0345" refid="bib55">55</ce:cross-ref>]. Docking- and pharmacophore-based virtual screening approaches effectively identified the structural features required to inhibit both JAK2 and JAK3, and screened for novel molecules with inhibitory activity. In addition, docking-based virtual screening had been reported to design some dual-target inhibitors, including CDK2-GSK3Î², EGFR-Src, Lck-Src, and Lck-VEGFR2, which were frequently co-expressed or coactivated in various types of cancer [<ce:cross-ref id="crosref0350" refid="bib56">56</ce:cross-ref>]. Eukaryotic type II topoisomerases, large homodimeric enzymes, can pass an unbroken strand and then reseal the break. In addition to inhibition of enzyme activity, topoisomerase II poisons generate DNA damage and delay cell cycle progression. The design of dual-target inhibitors can be also inspired by the cellular functions of the two targeted enzymes. As example, the non-kinases therapeutic targets topoisomerase II and Hsp90 formed a complex that enhanced the activity of topoisomerase II poison [<ce:cross-ref id="crosref0355" refid="bib57">57</ce:cross-ref>]. Thus, molecular modeling was used to designed dual-target inhibitors of topoisomerase II and Hsp90. Then, four candidate compounds were selected as possible dual-target inhibitors [<ce:cross-ref id="crosref0360" refid="bib58">58</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.2" view="all">
                     <ce:label>3.2</ce:label>
                     <ce:section-title id="sectitle0080">Pharmacophore-based drug design</ce:section-title>
                     <ce:para id="p0105" view="all">Access to atomic resolution information on the relevant proteins allows for the design of multi-target small molecules based on binding site structures. A structure-based approach enables the identification of drugs active against unrelated targets by taking advantage of common binding site features that are not apparent from protein sequence or ligand similarities. Pharmacophore-based drug design is a time-consuming approach, and parametrization has had a major impact on virtual screening.</ce:para>
                     <ce:para id="p0110" view="all">Recently, a pharmacophore model has been developed to define the structural features needed to access the type II binding conformation [<ce:cross-ref id="crosref0365" refid="bib59">59</ce:cross-ref>]. First, the model posits the essential elements: (a) a âheadâ heterocyclic motif occupying the adenosine binding pocket that typically makes one to three hydrogen bonds with the kinase hinge segment, (b) a linker moiety that traverses the region and is occupied by a âgatekeeperâ residue, (c) and a hydrogen-bond donor/acceptor motif and a hydrophobic âtailâ that occupy the pocket created by the flip of the âDFGâ motif of the kinase activation loop. Subsequently, a library of potential type II inhibitors was established based upon this model. Moreover, kinome-wide selectivity profiling of the library was performed to identify new inhibitors and kinases that might be susceptible to inhibition by type II inhibitors. A library containing approximately 100 potential type II inhibitors was screened against a panel of over 420 kinases. Two compounds that showed binding affinity for TGFÎ²-activated kinase 1 (TAK1) and mitogen-activated protein kinasekinase kinase kinase 2 (MAP4K2) emerged from this effort [<ce:cross-ref id="crosref0370" refid="bib60">60</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.3" view="all">
                     <ce:label>3.3</ce:label>
                     <ce:section-title id="sectitle0085">Fragment-based drug design</ce:section-title>
                     <ce:para id="p0115" view="all">Kinase fragment libraries are traditionally composed of small hinge binders. These binders consist of one or two fused aryl and/or heteroaryl ring systems with hydrogen-bond donors or acceptors. Such fragments are highly polar and can aggregate at millimolar concentrations, which is often essential to achieve activity in a biochemical fragment screen. Remarkably, achieving a good signal-to-noise ratio is the major challenge of this method. Novel skeleton inhibitors are developed, but these compounds are difficult to synthesize and have low activities.</ce:para>
                     <ce:para id="p0120" view="all">A kinase-directed fragment (KDF) library was designed to enhance sensitivity and interrogate binding at the kinase hinge more effectively [<ce:cross-ref id="crosref0375" refid="bib61">61</ce:cross-ref>]. This KDF library contained a diverse set of heterocyclic hinge region binders along with moieties that engage lipophilic pockets or the ribose sugar pocket. Accordingly, KDFs had larger molecular weights and were generally more active than the fragments contained in traditional libraries, permitting screening in the micromolar range. From such a library, a benzimidazole analogue had been identified as a promising starting platform for an RET TKI. Type-II inhibitors were generated by a VEGFR2 DFG-out template and an available RET sequence. Compound <ce:bold>21</ce:bold> effectively inhibited RET, RET mutants and VEGFR2 with all IC50Â <Â 1.0Â nM, which can block the blood supply required for RET-stimulated growth [<ce:cross-ref id="crosref0380" refid="bib62">62</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec3.4" view="all">
                     <ce:label>3.4</ce:label>
                     <ce:section-title id="sectitle0090">Artificial intelligence (AI)-based drug design</ce:section-title>
                     <ce:para id="p0125" view="all">Artificial intelligence (AI)-based design is based on the development of machine learning methods and the collection of big data from the molecular properties of drugs, structural biology, medicinal applications, pharmacological studies and omics initiatives [<ce:cross-ref id="crosref0385" refid="bib63">63</ce:cross-ref>]. Together, AI is destined to be an important developmental direction of precision medicine for innovative drug development. Thus, it will also bring a significant breakthrough to design new dual-target kinase drugs.</ce:para>
                     <ce:para id="p0130" view="all">Machine learning methods such as Bayesian models, support vector machines, and deep learning approaches have been widely used in the selection of target combinations and in virtual screening for designing dual-target kinase drugs. NaÃ¯ve Bayesian model was well-suited for integrating high-throughput data to predict functional protein connections. NaÃ¯ve Bayesian model was a very basic algorithm that was often used for classification. Compound <ce:bold>21</ce:bold>, a small-molecule activator, targeted both AMPK and ZIPK and induced cervical cancer cell apoptosis. The apoptotic PPI network was systematically constructed by NaÃ¯ve Bayesian model, and then apoptosis-related PPIs were predicted, including AMPK and ZIPK. A series of compounds possibly targeting both AMPK and ZIPK were screened and synthesized, and the novel dual-target activator BL-AD008 was eventually discovered for cancer therapy [<ce:cross-ref id="crosref0390" refid="bib64">64</ce:cross-ref>]. Drug discovery maps (DDMs), a machine learning model, showed the activity of a spectrum of compounds across the kinase family. DDMs visualized molecular similarity using state-of-the-art machine learning techniques. They can predict diverse kinase activities in small molecules. Obviously, this was an effective method to find dual-target kinase inhibitors. In addition, a computational framework had been also developed to identify therapeutic targets in cancer. First, a classifier integrates genomic and systematic data on diverse cancers to prioritize specific drug targets. Second, strategies were devised to select a set of anti-cancer drug targets by high-throughput screening, in which these targets were inhibited by small molecules. Combinatorial support vector machines (C-SVMs) were developed as virtual screening tools to search dual inhibitors for 11 combinations of 9 anti-cancer kinase targets (EGFR, VEGFR, PDGFR, Src, FGFR, Lck, CDK1, CDK2, GSK3). The C-SVM model was trained on a total of 233â1316 single-target inhibitors and 41â230 dual-target inhibitors. C-SVMs produced comparable dual-target inhibitor yields, slightly better kinase inhibitor false-hit rates, and significantly lower false-hit rates in a Zinc clean-leads data set compared to docking-based virtual screening methods such as Surflex-Dock and DOCK Blaster [<ce:cross-ref id="crosref0395" refid="bib65">65</ce:cross-ref>]. At present, one of the most popular methods of drug design was the artificial intelligence-driven model. The automatic chemical design and improvement of virtual screening by artificial intelligence will quicken the discovery of dual-target kinase inhibitors. The authors trained deep neural network with hundreds of thousands of existing chemical structures to build continuous molecular representations. By converting discrete molecular representations to and from a continuous multidimensional representation, continuous representations also allowed the use of powerful gradient-based optimization to efficiently guide the search for optimized functional compounds [<ce:cross-ref id="crosref0400" refid="bib66">66</ce:cross-ref>]. Moreover, a deep neural network, called DeepVS, was developed to learn how to extract relevant features from basic data by the AutoDock Vina and Dock programs [<ce:cross-ref id="crosref0405" refid="bib67">67</ce:cross-ref>].</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0095">Challenges and future perspectives</ce:section-title>
                  <ce:para id="p0135" view="all">Dual-target drugs have therapeutic advantages over the combination therapies because they weaken problems including different bioavailabilities, metabolisms, and antagonistic effects. Compared to single-target drugs, dual-target drugs may demonstrate either their additive or synergistic effects.</ce:para>
                  <ce:para id="p0140" view="all">Despite their evident growth, dual-targeted inhibitors are attributed with several challenges. A critical challenge is how to control the adverse effects of dual-targeted activities. The dual inhibitors still have selective activities against two targets. The primary targets are modulated at lower concentrations and the secondary targets need high doses, which lead to toxic side effects. This needs quantitative information about the potency of dual-targeted inhibitors, not only the biochemical or cell-based bioactivity. Another major limitation is that the pathways/mechanism of cancer are partially understood at the molecular levels. It limits the development of polypharmacological network without the complete data. The toxicities or targets of many reported inhibitors are insufficiently understood. The current dual-target kinase design strategies still have several drawbacks, including difficulty of addressing target flexibility. Addressing these problems in respective areas will be gradually overcome.</ce:para>
                  <ce:para id="p0145" view="all">Comprehensive target selectivity profiling is important for the adverse effects of dual-targeted activities. Except for analysis modeling results, data-driven computational models should design the target selectivity experiments, especially for experiments where the chemical spaces are too high-dimensional. In the process of discovering dual-target inhibitors, we should consider the efficacy <ce:italic>inÂ vitro</ce:italic> combined with <ce:italic>inÂ vivo</ce:italic> and phenotypic screening combined with target-based approaches. Sophisticated and comprehensive polypharmacology approaches are expected to further improve for less toxic dual-targeting inhibitor. Repurposing based on the reported mechanism and new target identification saves time and costs, which provides an opportunity for dual-targeted design. There are already screening efforts to identify new uses for existing agents. Phenotypic screening is also needed for more small-molecule compounds and target families. We hope collaborations between academia and pharmaceutical sector to join these efforts. For medicinal chemistry strategies, the number and diversity of chemical entity are the main problems of drug design. In a theory, more entities such as newly DNA-encoded chemical libraries, which contain billions of compounds can be easily produced within a few weeks for single-target or dual-target purposes, will take more opportunities to design the best dual-target kinase drugs. For computational strategies, with the rapid progress of AI-based technologies, multiple aspects can be developed into solving the problems of dual-target kinase drug design, including higher-quality datasets, new hypotheses and machine learning models, as well as more new algorithms and software packages in the near future.</ce:para>
               </ce:section>
               <ce:section id="sec5" role="conclusion" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0100">Conclusions</ce:section-title>
                  <ce:para id="p0150" view="all">Hitherto, more than 500 protein kinases have been reported encoded by the human genome, and most of them are able to regarded as potential drugable targets in cancer therapeutics. Accordingly, nearly 400 types of known kinase inhibitors have also been designed, which may be a relatively important branch of medicinal chemistry. Since the first targeted small-molecule kinase inhibitor, imatinib, is applied into the clinic, more than forty types of small-molecule kinase inhibitors have been approved for the treatment of different types of human cancers so far. However, the inherent mechanisms of protein kinases may lead to the ineffectiveness of such small-molecule drugs and corresponding resistant or compensatory mechanisms to their targeted kinases in cancer therapy. Under some circumstances, accumulating evidence has recently demonstrated that one kinase (e.g., ERK5) may provide a common bypass route (also called resistant or compensatory mechanism), which rescues cell proliferation upon abrogation of another kinase signaling (e.g., ERK1). Thus, it seems to be meaningful to develop new design strategies or combination approaches for dual-target kinase drug discovery for future cancer therapy.</ce:para>
                  <ce:para id="p0155" view="all">As mentioned above, we focus on providing the current drug design strategies aiming at dual-target kinase, mainly referring to medicinal chemistry design (e.g., drug repurposing, skeleton modification, and linked/merged/fused pharmacophore), computational design (e.g., docking-, pharmacophore-, fragment-based, and even artificial intelligence (AI)-based design approaches). These dual-target drug design strategies are as follows: (1) Drug repurposing is the direct application of multiple pharmacology methods. The recycling of the compounds possesses adequate research foundation. (2) Skeleton modification of lead drugs may be an effective approach to obtain candidate compounds for drug design. (3) Linker pharmacophore approach is useful to aid design of more potent dual-target kinase small molecules. This method of design is an improvement over the above-mentioned two methods, but a problem of the blood brain barrier still exists. (4) Hybridized and merged pharmacophores seem so similar, and they involve the candidate small-molecule compounds with smaller molecular weight than linker pharmacophore approach. (5) For some protein kinases with no targeted drug, receptor-based drug design is acceptable. Based upon calculation methods, it can produce a variety of new candidate compounds. (6) AI-based method will become a key to precision medicine for innovative drug development. The aforementioned medicinal chemistry and computational design strategies are summarized, and their pros and cons are also demonstrated (<ce:cross-ref id="crosref0410" refid="fig3">Fig.Â 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>). Collectively, it is reasonable to expect that design of dual-target kinase drugs would become increasingly popular in the battle against kinase drug resistant or compensatory mechanisms for cancer therapeutics.</ce:para>
                  <ce:para id="p0160" view="all">However, there Moreover, in this review, we mainly focus on dual-target kinase drugs in cancer, but other types of dual-target drugs have been emerging in the current cancer therapy as well.</ce:para>
                  <ce:para id="p0165" view="all">In summary, the combination of medicinal chemistry and computational strategies will together provide a new insight into the future directions of dual-target kinase (maybe not limited to kinases) drug design to overcome the resistance or compensatory mechanisms for the current and future cancer therapeutics.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0105">Declaration of competing interest</ce:section-title>
               <ce:para id="p0170" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0110">Acknowledgements</ce:section-title>
               <ce:para id="p0175" view="all">This work was supported by grants from the <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (Grant No. 81922064, Grant No. <ce:grant-number refid="gs2">81673455</ce:grant-number>, Grant No. <ce:grant-number refid="gs2">81874290</ce:grant-number> and Grant No. <ce:grant-number refid="gs2">81673290</ce:grant-number>).</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="all">
                  <ce:section-title id="sectitle0115">Abbreviations</ce:section-title>
                  <ce:para id="p0180" view="all">
                     <ce:def-list id="dlist0010">
                        <ce:def-term id="d0010">AI</ce:def-term>
                        <ce:def-description id="defdis0010">
                           <ce:para id="p0185" view="all">artificial intelligence</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0015">AMPK</ce:def-term>
                        <ce:def-description id="defdis0015">
                           <ce:para id="p0190" view="all">adenosine monophosphate-activated protein kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0020">ATP</ce:def-term>
                        <ce:def-description id="defdis0020">
                           <ce:para id="p0195" view="all">adenosine 5â²-triphosphate</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0025">AurA</ce:def-term>
                        <ce:def-description id="defdis0025">
                           <ce:para id="p0200" view="all">aurora kinase A</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0030">CDK-2</ce:def-term>
                        <ce:def-description id="defdis0030">
                           <ce:para id="p0205" view="all">cyclin-dependent kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0035">C-SVM</ce:def-term>
                        <ce:def-description id="defdis0035">
                           <ce:para id="p0210" view="all">combinatorial support vector machines</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0040">DDM</ce:def-term>
                        <ce:def-description id="defdis0040">
                           <ce:para id="p0215" view="all">drug discovery maps</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0045">EGFR</ce:def-term>
                        <ce:def-description id="defdis0045">
                           <ce:para id="p0220" view="all">epidermal growth factor receptor</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0050">ERK</ce:def-term>
                        <ce:def-description id="defdis0050">
                           <ce:para id="p0225" view="all">extracellular regulated kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0055">FDA</ce:def-term>
                        <ce:def-description id="defdis0055">
                           <ce:para id="p0230" view="all">food and drug administration</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0060">GBM</ce:def-term>
                        <ce:def-description id="defdis0060">
                           <ce:para id="p0235" view="all">glioblastoma multiforme</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0065">GSK-3Î²</ce:def-term>
                        <ce:def-description id="defdis0065">
                           <ce:para id="p0240" view="all">glycogen synthase kinase 3B</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0070">HDAC</ce:def-term>
                        <ce:def-description id="defdis0070">
                           <ce:para id="p0245" view="all">histone deacetylase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0075">JAK2</ce:def-term>
                        <ce:def-description id="defdis0075">
                           <ce:para id="p0250" view="all">janus kinase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0080">KDF</ce:def-term>
                        <ce:def-description id="defdis0080">
                           <ce:para id="p0255" view="all">kinase-directed fragment</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0085">MAPK</ce:def-term>
                        <ce:def-description id="defdis0085">
                           <ce:para id="p0260" view="all">mitogen-activated protein kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0090">MAP4K2</ce:def-term>
                        <ce:def-description id="defdis0090">
                           <ce:para id="p0265" view="all">mitogen-activated protein kinase kinase kinase kinase 2</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0095">mTOR</ce:def-term>
                        <ce:def-description id="defdis0095">
                           <ce:para id="p0270" view="all">mammalian target of rapamycin</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0100">NSCLC</ce:def-term>
                        <ce:def-description id="defdis0100">
                           <ce:para id="p0275" view="all">nonâsmall cell lung cancer</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0105">PDK1</ce:def-term>
                        <ce:def-description id="defdis0105">
                           <ce:para id="p0280" view="all">phosphoinositide dependent kinase-1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0110">PK</ce:def-term>
                        <ce:def-description id="defdis0110">
                           <ce:para id="p0285" view="all">pharmacokinetics</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0115">PI3K</ce:def-term>
                        <ce:def-description id="defdis0115">
                           <ce:para id="p0290" view="all">phosphoinositide 3 -kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0120">PPIs</ce:def-term>
                        <ce:def-description id="defdis0120">
                           <ce:para id="p0295" view="all">protein-protein interactions</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0125">RTK</ce:def-term>
                        <ce:def-description id="defdis0125">
                           <ce:para id="p0300" view="all">receptor tyrosine kinase</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0130">Ks</ce:def-term>
                        <ce:def-description id="defdis0130">
                           <ce:para id="p0305" view="all">tyrosine kinase inhibitors</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0135">TAK1</ce:def-term>
                        <ce:def-description id="defdis0135">
                           <ce:para id="p0310" view="all">TGFÎ²-activated kinase 1</ce:para>
                        </ce:def-description>
                        <ce:def-term id="d0140">TSC2</ce:def-term>
                        <ce:def-description id="defdis0140">
                           <ce:para id="p0315" view="all">tuberous sclerosis complex 2</ce:para>
                        </ce:def-description>
                     </ce:def-list>
                  </ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0120">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Bhullar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.O.</ce:given-name>
                                 <ce:surname>LagarÃ³n</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>McGowan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Parmar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.P.</ce:given-name>
                                 <ce:surname>Hubbard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.V.</ce:given-name>
                                 <ce:surname>Rupasinghe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Kinase-targeted cancer therapies: progress, challenges and future directions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>48</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">K.S. Bhullar, N.O. Lagaron, E.M. McGowan, I. Parmar, A. Jha, B.P. Hubbard, H.P.V. Rupasinghe, Kinase-targeted cancer therapies: progress, challenges and future directions, Molecular Cancer 17 (2018) 48.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein kinasesâthe major drug targets of the twenty-first century?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                              <sb:last-page>315</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">P. Cohen, Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug. Discovery 1 (2002) 309-315.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Anastassiadis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Deacon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Devarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Peterson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1039</sb:first-page>
                              <sb:last-page>1045</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, J.R. Peterson, Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity, Nat. Biotechnol. 29 (2011) 1039-1045.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hughes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.I.</ce:given-name>
                                 <ce:surname>Andersson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>459</sb:first-page>
                              <sb:last-page>471</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">D. Hughes, D.I. Andersson, Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms, Nat. Rev. Genet. 16 (2015) 459-471.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Rudmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>On-target and off-target-based toxicologic effects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Toxicol. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>310</sb:first-page>
                              <sb:last-page>314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">D.G. Rudmann, On-target and off-target-based toxicologic effects, Toxicol. Pathol. 41 (2013) 310-314.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Parveen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Sahoo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polymeric nanoparticles for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Drug Target.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>123</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">S. Parveen, S.K. Sahoo, Polymeric nanoparticles for cancer therapy, J. Drug Target 16 (2008) 108-123.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Cocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Schram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kulick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Misale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Won</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Yaeger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Razavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ptashkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Hechtman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Toska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cownie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Somwar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shifman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mattar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>SelÃ§uklu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Samoila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Guzman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Tuch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ebata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>de Stanchina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Nagy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Lanman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Houck-Loomis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ladanyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Hyman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Scaltriti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resistance to TRK inhibition mediated by convergent MAPK pathway activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1422</sb:first-page>
                              <sb:last-page>1427</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">E. Cocco, A.M. Schram, A. Kulick, S. Misale, H.H. Won, R. Yaeger, P. Razavi, R. Ptashkin, J.F. Hechtman, E. Toska, J. Cownie, R. Somwar, S. Shifman, M. Mattar, S.D. Selcuklu, A. Samoila, S. Guzman, B.B. Tuch, K. Ebata, E. de Stanchina, R.J. Nagy, R.B. Lanman, B. Houck-Loomis, J.A. Patel, M.F. Berger, M. Ladanyi, D.M. Hyman, A. Drilon, M. Scaltriti, Resistance to TRK inhibition mediated by convergent MAPK pathway activation, Nat. Med. 25 (2019) 1422-1427.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Staunton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Zimmermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Borisy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synergistic drug combinations tend to improve therapeutically relevant selectivity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>659</sb:first-page>
                              <sb:last-page>666</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">J.E. Staunton, X. Jin, M.S. Lee, G.R. Zimmermann, A.A. Borisy, Synergistic drug combinations tend to improve therapeutically relevant selectivity, Nat. Biotechnol. 27 (2009) 659-666.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Mayes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Eastman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yadavilli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Seestaller-Wehr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hopson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tsvetkov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Smothers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hoos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1639</sb:first-page>
                              <sb:last-page>1651</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">L. Liu, P.A. Mayes, S. Eastman, H. Shi, S. Yadavilli, T. Zhang, J. Yang, L. Seestaller-Wehr, S. Y. Zhang, C. Hopson, L. Tsvetkov, J. Jing, S. Zhang, J. Smothers, A. Hoos, The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4, Clin. Cancer Res. 21 (2015) 1639-1651.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Pratilas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Viale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Solit</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rosen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U.S.A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4519</sb:first-page>
                              <sb:last-page>4524</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">C.A. Pratilas, B.S. Taylor, Q. Ye, A. Viale, C. Sander, D.B. Solit, N. Rosen, BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway, Proc. Natl. Acad. Sci. U S A. 106 (2009) 4519-4524.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Lavoie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sahmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Maisonneuve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Marullo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Thevakumaran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kurinov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Sicheri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Therrien</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MEK drives BRAF activation through allosteric control of KSR proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>554</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>549</sb:first-page>
                              <sb:last-page>553</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">H. Lavoie, M. Sahmi, P. Maisonneuve, S.A. Marullo, N. Thevakumaran, T. Jin, I. Kurinov, F. Sicheri, M. Therrien, MEK drives BRAF activation through allosteric control of KSR proteins, Nature. 554 (2018) 549-553.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Heynen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Prahallad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Robert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Haanen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Blank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wesseling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Willems</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zecchin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hobor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Bajpe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lieftink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mateus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Vagner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Grernrum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Hofland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schlicker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Wessels</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Beijersbergen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.Di</ce:given-name>
                                 <ce:surname>Bardelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Nicolantonio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Eggermont</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bernards</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>508</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>118</sb:first-page>
                              <sb:last-page>122</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">C. Sun, L. Wang, S. Huang, G.J. Heynen, A. Prahallad, C. Robert, J. Haanen, C. Blank, J. Wesseling, S.M. Willems, D. Zecchin, S. Hobor, P.K. Bajpe, C. Lieftink, C. Mateus, S. Vagner, W. Grernrum, I. Hofland, A. Schlicker, L.F. Wessels, R.L. Beijersbergen, A.Di. Bardelli, F. Nicolantonio, A.M. Eggermont, R. Bernards, Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma, Nature. 508 (2014) 118-122.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Maemondo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kobayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sugawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Oizumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Isobe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gemma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Harada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yoshizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Kinoshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Fujita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Okinaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hirano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yoshimori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Harada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ogura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ando</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miyazawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Saijo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hagiwara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Morita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nukiwa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>North-East Japan Study Group. Gefitinib or chemotherapy for nonâsmall-cell lung cancer with mutated EGFR</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N.Â Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>362</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2380</sb:first-page>
                              <sb:last-page>2388</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita, T. Nukiwa, North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med. 362 (2010) 2380-2388.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Polypharmacology: drug discovery for the future</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Rev. Clin. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>47</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">A.S. Reddy, S. Zhang, Polypharmacology: drug discovery for the future, Expert Rev. Clin. Pharmacol. 6(2013) 41-47.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.N.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bhatt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rotow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rohrberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Olivas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.E.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hemmati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Martins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Maynard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kuhn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Galeas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Donnella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kaushik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dumont</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Krings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Haringsma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Robillard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Simmons</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.C.</ce:given-name>
                                 <ce:surname>Harding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>McCormick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Blakely</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Bivona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bandyopadhyay</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>118</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">K.N. Shah, R. Bhatt, J. Rotow, J. Rohrberg, V. Olivas, V.E. Wang, G. Hemmati, M.M. Martins, A. Maynard, J. Kuhn, J. Galeas, H.J. Donnella, S. Kaushik, A. Ku, S. Dumont, G. Krings, H.J. Haringsma, L. Robillard, A.D. Simmons, T.C. Harding, F. McCormick, A. Goga, C.M. Blakely, T.G. Bivona, S. Bandyopadhyay, Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer, Nat. Med. 25 (2019) 111-118.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.F.S.A.</ce:given-name>
                                 <ce:surname>Ribeiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.M.</ce:given-name>
                                 <ce:surname>Alessi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.C.</ce:given-name>
                                 <ce:surname>Oliveira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.L.</ce:given-name>
                                 <ce:surname>Gongora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.P.</ce:given-name>
                                 <ce:surname>Sacardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Zucchetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Shimada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>de Galiza Barbosa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Katz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: a case series</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lung Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>139</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9</sb:first-page>
                              <sb:last-page>12</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">M.F.S.A Ribeiro, J.V.M. Alessi, L.J.C. Oliveira, A.B.L. Gongora, K.P. Sacardo, B.M. Zucchetti, A.K. Shimada, F. de Galiza Barbosa, O. Feher, A. Katz, Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series, Lung Cancer 139 (2019) 9-12.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Roskoski</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Properties of FDA-approved small molecule protein kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>144</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">R.Jr. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors, Pharmacol. Res. 144 (2019) 19-50.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Inoki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Guan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TSC2 mediates cellular energy response to control cell growth and survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>577</sb:first-page>
                              <sb:last-page>590</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">K. Inoki, T. Zhu, K.L. Guan, TSC2 mediates cellular energy response to control cell growth and survival, Cell 115 (2003) 577-590.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Plews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mohd Yusof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Saji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Ringel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Phay</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Clin. Endocrinol. Metab.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>748</sb:first-page>
                              <sb:last-page>756</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">R.L. Plews, A. Mohd Yusof, C. Wang, M. Saji, X. Zhang, C.S. Chen, M.D. Ringel, J.E. Phay, A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth, J. Clin. Endocrinol. Metab. 100 (2015) 748-756.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Manetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.A.</ce:given-name>
                                 <ce:surname>Locatelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Maga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schenone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Modugno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Forli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Corelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AÂ combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3278</sb:first-page>
                              <sb:last-page>3286</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">F. Manetti, G.A. Locatelli, G. Maga, S. Schenone, M. Modugno, S. Forli, F. Corelli, M. Botta, A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors, J. Med. Chem. 49 (2006) 3278-3286.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Stashko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Minson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Cummings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Glaros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Newton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sather</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kireev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Janzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Frye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7031</sb:first-page>
                              <sb:last-page>7041</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">W. Zhang, D. DeRyckere, D. Hunter, J. Liu, M.A. Stashko, K.A. Minson, C.T. Cummings, M. Lee, T.G. Glaros, D.L. Newton, S. Sather, D. Zhang, D. Kireev, W.P. Janzen, H.S. Earp, D.K. Graham, S.V. Frye, X. Wang, UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor, J. Med. Chem. 57 (2014) 7031-7041.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andrs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Korabecny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hodny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bartek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kuca</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>71</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">M. Andrs, J. Korabecny, D. Jun, Z. Hodny, J. Bartek, K. Kuca, Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring, J. Med. Chem. 58 (2015) 41-71.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nacht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.P.</ce:given-name>
                                 <ce:surname>Sheets</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.St</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Labenski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mazdiyasni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Karp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Chaturvedi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhavsar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Niu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Westlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Petter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Medikonda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3KÎ±</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>712</sb:first-page>
                              <sb:last-page>721</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">M. Nacht, L. Qiao, M.P. Sheets, T.St. Martin, M. Labenski, H. Mazdiyasni, R. Karp, Z. Zhu, P. Chaturvedi, D. Bhavsar, D. Niu, W. Westlin, R.C. Petter, A.P. Medikonda, J. Singh, Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3KÎ±, J. Med. Chem. 56 (2013) 712-721.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4023</sb:first-page>
                              <sb:last-page>4035</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">M. Zhan, Y. Deng, L. Zhao, G. Yan, F. Wang, Y. Tian, L. Zhang, H. Jiang, Y. Chen, Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors, J. Med. Chem. 60 (2017) 4023-4035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lomahan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Tran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Grenlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Suganami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ikegaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase A is a possible target of OSU-03012 to destabilize MYC family proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Rep.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>901</sb:first-page>
                              <sb:last-page>905</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">A. Silva, J. Wang, S. Lomahan, T.A. Tran, L. Grenlin, A. Suganami, Y. Tamura, N. Ikegaki, Aurora kinase A is a possible target of OSU-03012 to destabilize MYC family proteins, Oncol. Rep. 32 (2014) 901-905.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Daniele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sestito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pietrobono</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Giacomelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Chiellini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Di Maio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Marinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Martini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rapposelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of PDK1 and aurora kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>100</sb:first-page>
                              <sb:last-page>114</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">S. Daniele, S. Sestito, D. Pietrobono, C. Giacomelli, G. Chiellini, D. Di Maio, L. Marinelli, E. Novellino, C. Martini, S. Rapposelli, Dual Inhibition of PDK1 and Aurora Kinase A: An Effective Strategy to Induce Differentiation and Apoptosis of Human Glioblastoma Multiforme Stem Cells, ACS Chem. Neurosci. 8 (2017) 100-114.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nomanbhoy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gurbani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Patricelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Herhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pauls</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Buhrlage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sapkota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Westover</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of type II inhibitors of TGFÎ²-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>183</sb:first-page>
                              <sb:last-page>196</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">L. Tan, T. Nomanbhoy, D. Gurbani, M. Patricelli, J. Hunter, J. Geng, L. Herhaus, J. Zhang, E. Pauls, Y. Ham, H.G. Choi, T. Xie, X. Deng, S.J. Buhrlage, T. Sim, P. Cohen, G. Sapkota, K.D. Westover, N.S. Gray, Discovery of type II inhibitors of TGFÎ²-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2), J. Med. Chem. 58 (2015) 183-196.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Riggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nagy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Elsner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Erdman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Cashion</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Robinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tehrani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Deyanat-Yazdi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.K.</ce:given-name>
                                 <ce:surname>Narla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Barnes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Katz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Moghaddam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bahmanyar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pagarigan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Delker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>LeBrun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Chamberlain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Calabrese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.S.</ce:given-name>
                                 <ce:surname>Canan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Leftheris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Boylan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor for the treatment of triple negative breast cancer initiated from a phenotypic screen</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8989</sb:first-page>
                              <sb:last-page>9002</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">J.R. Riggs, M. Nagy, J. Elsner, P. Erdman, D. Cashion, D. Robinson, R. Harris, D. Huang, L. Tehrani, G. Deyanat-Yazdi, R.K. Narla, X. Peng, T. Tran, L. Barnes, T. Miller, J. Katz, Y. Tang, M. Chen, M.F. Moghaddam, S. Bahmanyar, B. Pagarigan, S. Delker, L. LeBrun, P.P. Chamberlain, A. Calabrese, S.S. Canan, K. Leftheris, D. Zhu, J.F. Boylan, The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen, J. Med. Chem. 60 (2017) 8989-9002.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.O.</ce:given-name>
                                 <ce:surname>Yosief</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dhawan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Muthengi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Buckley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Perry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Bradner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-guided design and development of potent and selective dual bromodomain 4 (BRD4)/Polo-like kinase 1 (PLK1) inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7785</sb:first-page>
                              <sb:last-page>7795</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">S. Liu, H.O. Yosief, L. Dai, H. Huang, G. Dhawan, X. Zhang, A.M. Muthengi, J. Roberts, D.L. Buckley, J.A. Perry, L. Wu, J.E. Bradner, J. Qi, W. Zhang, Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors, J. Med. Chem. 61 (2018) 7785-7795.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Baxi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Goulet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.O.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Knighton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Marx</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Walls</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Wells</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zientek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04979064 through structure-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>91</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">H. Cheng, C. Li, S. Bailey, S.M. Baxi, L. Goulet, L. Guo, J. Hoffman, Y. Jiang, T.O. Johnson, T.W. Johnson, D.R. Knighton, J. Li, K.K. Liu, Z. Liu, M.A. Marx, M. Walls, P.A. Wells, M.J. Yin, J. Zhu, M. Zientek, Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design, ACS. Med. Chem. Lett. 4 (2012) 91-97.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological evaluation of dimorpholine substituted thienopyrimidines as potential class I PI3K/mTOR dual inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4023</sb:first-page>
                              <sb:last-page>4035</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">M. Zhan, Y. Deng, L. Zhao, G. Yan, F. Wang, Y. Tian, L. Zhang, H. Jiang, Y. Chen, Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors, J. Med. Chem. 60 (2017) 4023-4035.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Barrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Bridges</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Dudley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Saltiel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Fergus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Flamme</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Delaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kaufman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>LePage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.R.</ce:given-name>
                                 <ce:surname>Leopold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Przybranowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sebolt-Leopold</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Van Becelaere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Doherty</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Kennedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Marston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.A.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Warmus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Tecle</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6501</sb:first-page>
                              <sb:last-page>6504</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">S.D. Barrett, A.J. Bridges, D.T. Dudley, A.R. Saltiel, J.H. Fergus, C.M. Flamme, A.M. Delaney, M. Kaufman, S. LePage, W.R. Leopold, S.A. Przybranowski, J. Sebolt-Leopold, K. Van Becelaere, A.M. Doherty, R.M. Kennedy, D. Marston, Jr. Howard WA, Y. Smith, J.S. Warmus, H. Tecle, The discovery of thebenzhydroxamate MEK inhibitors CI-1040 and PD 0325901, Bioorg Med Chem Lett. 18 (2008) 6501-6504</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Van Dort</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Nino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Lombardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Blanks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Galban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Ross</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2512</sb:first-page>
                              <sb:last-page>2522</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">M.E. Van Dort, H. Hong, H. Wang, C.A. Nino, R.L. Lombardi, A.E. Blanks, S. Galban, B.D. Ross, Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K), J. Med. Chem. 59 (2016) 2512-2522.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Parikh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Grant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Kellogg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>125</sb:first-page>
                              <sb:last-page>137</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">K. Liu, W. Rao, H. Parikh, Q. Li, T.L. Guo, S. Grant, G.E. Kellogg, S. Zhang, 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization, Eur. J. Med. Chem. 47 (2012) 125â137.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Boerner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Demory</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Silva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Parsons</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7059</sb:first-page>
                              <sb:last-page>7071</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">J.L. Boerner, M.L. Demory, C. Silva, S.J. Parsons, Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II, Mol. Cell Biol. 24 (2004) 7059-7071.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>BarchÃ©chath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Saade</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lauwagie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jean-Claude</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational design of multitargeted tyrosine kinase inhibitors: a novel approach</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>73</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>380</sb:first-page>
                              <sb:last-page>387</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">S. Barchechath, C. Williams, K. Saade, S. Lauwagie, B. Jean-Claude, Rational design of multitargeted tyrosine kinase inhibitors: a novel approach, Chem. Biol. Drug Des. 73 (2009) 380-387.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Larroque-Lombard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lauwagie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Halaoui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Coudray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Jean-Claude</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>80</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>981</sb:first-page>
                              <sb:last-page>991</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">AL. Larroque-Lombard, N. Ning, S. Rao, S. Lauwagie, R. Halaoui, L. Coudray, Y. Huang, B.J. Jean-Claude, Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor, Chem. Biol. Drug. Des. 80 (2012) 981-991.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.R.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Cha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Ha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Ryu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.G.</ce:given-name>
                                 <ce:surname>Suh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. N. Y. Acad. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>393</sb:first-page>
                              <sb:last-page>403</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">J.H. Choi, Y.R. Yang, S.K. Lee, S.H. Kim, Y.H. Kim, J.Y. Cha, S.W. Oh, J.R. Ha, S.H. Ryu, P.G. Suh, Potential inhibition of PDK1/Akt signaling by phenothiazines suppresses cancer cell proliferation and survival, Ann. N. Y. Acad. Sci. 1138 (2008) 393-403.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Larroque-Lombard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Todorova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Qiyu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jean-Claude</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol. Drug Des.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>77</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>309</sb:first-page>
                              <sb:last-page>318</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">A.L. Larroque-Lombard, M. Todorova, Q. Qiyu, B. Jean-Claude, Synthesis and studies on three-compartment flavone-containing combi-molecules designed to target EGFR, DNA, and MEK, Chem. Biol. Drug Des. 77 (2011) 309-318.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Miao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecules simultaneously inhibiting p53-murine double minute 2 (MDM2) interaction and histone deacetylases (HDACs): discovery of novel multitargeting antitumor agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7245</sb:first-page>
                              <sb:last-page>7260</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">S. He, G. Dong, S. Wu, K. Fang, Z. Miao, W. Wang, C. Sheng, Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents, J. Med. Chem. 61 (2018) 7245-7260.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1230</sb:first-page>
                              <sb:last-page>1241</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">Z. Zhao, H. Wu, L. Wang, Y. Liu, S. Knapp, Q. Liu, N. S. Gray, Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem. Biol. 9 (2014) 1230-1241.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B. Wang F.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S. Qi W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a novel highly potent type II ABL/KIT dual kinase inhibitor with a distinct hinge binding</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>273</sb:first-page>
                              <sb:last-page>289</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">Q. Wang, F. Liu, B. Wang F. Zou, Z. Qi, C. Chen, K. Yu, C. Hu, S. Qi W. Wang, Z. Hu, J. Liu, W. Wang, L. Wang, Q. Liang, S. Zhang, T. Ren, Q. Liu, J. Liu, Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3- (trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding, J. Med. Chem. 60 (2017) 273-289.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cory</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The Bcl-2 apoptotic switch in cancer, development and therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1324</sb:first-page>
                              <sb:last-page>1337</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">J. M. Adams, S. Cory, The Bcl-2 apoptotic switch in cancer, development and therapy, Oncogene 26 (2007) 1324-1337</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Labi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Erlacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kiessling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Villunger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BH3-only proteins in cell death initiation, malignant disease and anticancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1325</sb:first-page>
                              <sb:last-page>1338</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">V. Labi, M. Erlacher, S. Kiessling, A. Villunger, BH3-only proteins in cell death initiation, malignant disease and anticancer therapy, Cell Death Differ. 13 (2006) 1325-1338.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Wendt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1123</sb:first-page>
                              <sb:last-page>1143</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">M.D. Wendt, Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction, Expert Opin. Drug Discovery 3 (2008) 1123-1143.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Aikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nishida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Homma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sogabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Igaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Hayano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sameshima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Miyahisa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kawamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tawada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Imai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Inazuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Imaeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ishikaw</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9635</sb:first-page>
                              <sb:last-page>9645</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">Y. Tanaka, K. Aikawa, G. Nishida, M. Homma, S. Sogabe, S. Igaki, Y. Hayano, T. Sameshima, I. Miyahisa, T. Kawamoto, M. Tawada, Y. Imai, M. Inazuka, N. Cho, Y. Imaeda, T. Ishikaw, Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins, J. Med. Chem. 56 (2013) 9635-9645.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Ocana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Vera-Badillo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Al-Mubarak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Templeton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Corrales-Sanchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Diez-Gonzalez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Cuenca-Lopez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Seruga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pandiella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Amir</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e95219</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">A.F. Ocana, M. Vera-Badillo, A. J. Al-Mubarak, V. Templeton, L. Corrales-Sanchez, L. Diez-Gonzalez, M. D. Cuenca-Lopez, B. Seruga, A. Pandiella, E. Amir, Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis, PLoS. ONE. 9 (2014) e95219.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hauschild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Grob</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.V.</ce:given-name>
                                 <ce:surname>Demidov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Jouary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gutzmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Millward</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rutkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.U.</ce:given-name>
                                 <ce:surname>Blank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kaempgen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>MartÃ­n-Algarra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Karaszewska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Mauch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Chiarion-Sileni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Swann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Haney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mirakhur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.E.</ce:given-name>
                                 <ce:surname>Guckert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Goodman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.B.</ce:given-name>
                                 <ce:surname>Chapman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Lancet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>380</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>358</sb:first-page>
                              <sb:last-page>365</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">A. Hauschild, JJ. Grob, LV. Demidov, T. Jouary, R. Gutzmer, M. Millward, P. Rutkowski, C.U. Blank, WH.Jr. Miller, E. Kaempgen, S. Martin-Algarra, B. Karaszewska, C. Mauch, V. Chiarion-Sileni, A.M. Martin, S.Swann, P. Haney, B. Mirakhur, M.E. Guckert, V. Goodman, P.B. Chapman, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380 (2012) 358-365.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sweetlove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Wrightson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kolekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.W.</ce:given-name>
                                 <ce:surname>Rewcastle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Baguley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Shepherd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Jamieson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>135</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">M. Sweetlove, E. Wrightson, S. Kolekar, G.W. Rewcastle, B.C. Baguley, P.R. Shepherd, S.M. Jamieson, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth. Front. Oncol. 5 (2015) 135.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Hei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Xin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Q.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2445</sb:first-page>
                              <sb:last-page>2455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">H.Y. Wang, Y. Shen, H. Zhang, Y.Y. Hei, H.Y. Zhao, M. Xin, S.M. Lu, S.Q. Zhang, Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. Future Med. Chem. 2018, 10, 2445-2455.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Qin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>997</sb:first-page>
                              <sb:last-page>1011</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Y. Chen, Y. Zheng, Q. Jiang, F. Qin, Y. Zhang, L. Fu, G. He, Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells, Eur. J. Med. Chem. 127 (2017) 997-1011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.G.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Mustafa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Ramanujulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design and synthesis of Janus kinase 2 (JAK2) and histone deacetlyase (HDAC) bispecific inhibitors based on pacritinib and evidence of dual pathway inhibition in hematological cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8233</sb:first-page>
                              <sb:last-page>8262</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">E.G. Yang, N. Mustafa, E.C. Tan, A. Poulsen, P.M. Ramanujulu, W.J. Chng, J.J. Yen, B.W. Dymock, Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines, J. Med. Chem. 59 (2016)8233-8262.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Behrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>MÃ¼ller-Newen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Schaper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Graeve</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>334</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>297</sb:first-page>
                              <sb:last-page>314</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">P.C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, L. Graeve, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochem. J. 334 (1998) 297-314.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Go</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Low</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>In-silico approaches to multi-target drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharm. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>739</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">X.H. Ma, Z. Shi, C. Tan, Y. Jiang, M.L. Go, B.C. Low, Y.Z. Chen, In-Silico Approaches to Multi-target Drug Discovery. Pharm. Res. 27 (2010) 739-749.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>982</sb:first-page>
                              <sb:last-page>996</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">S. Zhou, Y. Li, T. Hou, Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors, J. Chem. Inf. Model. 53 (2013) 982-996.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Arooj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sakkiah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e60470</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">M. Arooj, S. Sakkiah, G. Cao, K. W. Lee, An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes, PLoS One. 8 (2013) e60470.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Nitiss</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>DNA topoisomerase II and its growing repertoire of biological functions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>327</sb:first-page>
                              <sb:last-page>337</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">J.L. Nitiss, DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer. 9 (2009) 327-337.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.Y.</ce:given-name>
                                 <ce:surname>Jun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Proposal of dual inhibitor targeting ATPase domains of topoisomerase II and heat shock protein 90</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomol. Ther. (Seoul)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>453</sb:first-page>
                              <sb:last-page>468</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">K.Y. Jun, Y. Kwon, Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90, Biomol. Ther (Seoul). 24 (2016) 453-468.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rational design of inhibitors that bind to inactive kinase conformations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>358</sb:first-page>
                              <sb:last-page>364</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">Y. Liu, N.S. Gray, Rational design of inhibitors that bind to inactive kinase conformations, Nat. Chem. Biol. 2 (2006) 358-364.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.V.</ce:given-name>
                                 <ce:surname>Miduturu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kwiatkowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Brault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Filippakopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Chung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schwaller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>King</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Herrgard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zarrinkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>868</sb:first-page>
                              <sb:last-page>879</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">C. V. Miduturu, X. Deng, N. Kwiatkowski, W. Yang, L. Brault, P. Filippakopoulos, E. Chung, Q. Yang, J. Schwaller, S. Knapp, R. W. King, J. D. Lee, S. Herrgard, P. Zarrinkar, N. S. Gray, Highthroughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors, Chem. Biol. 18 (2011) 868-879.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>De Kloe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.R.</ce:given-name>
                                 <ce:surname>Leurs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.J.P.</ce:given-name>
                                 <ce:surname>de Esch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transforming fragments into candidates: small becomes big in medicinal chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov. Today</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>630</sb:first-page>
                              <sb:last-page>646</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">G.E. De Kloe, D. Bailey, R.R. Leurs, I.J.P. de Esch, Transforming fragments into candidates: small becomes big in medicinal chemistry, Drug Discovery Today. 14 (2009) 630-646.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Frett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Carlomagno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Moccia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Brescia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Federico</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>DeFalco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Admire</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Santoro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based discovery of a dual pan-RET/VEGFR2 kinase inhibitor optimized for single-agent polypharmacology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Angew. Chem. Int. Ed.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8717</sb:first-page>
                              <sb:last-page>8721</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">B. Frett, F. Carlomagno, M.L. Moccia, A. Brescia, G. Federico, V. DeFalco, B. Admire, Z. Chen, W. Qi, M. Santoro, H. Li, Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology, Angew. Chem. Int. Ed. 54 (2015) 8717-8721.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hessler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Baringhaus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Artificial intelligence in drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1191</sb:first-page>
                              <sb:last-page>1204</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">G. Hessler, K.H. Baringhaus, Artificial Intelligence in Drug Design, Molecules 61 (2018) 1191-1204.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Tong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ouyang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8071</sb:first-page>
                              <sb:last-page>8088</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">L. Fu, S. Zhang, L. Zhang, X. Tong, J. Zhang, Y. Zhang, L. Ouyang, B. Liu, J. Huang, Systems biology network-based discovery of a small molecule activator BL-AD008 targeting AMPK/ZIPK and inducing apoptosis in cervical cancer, Oncotarget 6 (2015) 8071-8088.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.H.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Rao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Go</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Low</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharm.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45</sb:first-page>
                              <sb:last-page>1560</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">X.H. Ma, R. Wang, C.Y. Tan, Y. Y. Jiang, T. Lu, H. B. Rao, X. Y. Li, M. L. Go, B. C. Low, Y. Z. Chen, Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol. Pharm. 7 (2010) 45-1560.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>GÃ³mez-Bombarelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Duvenaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>HernÃ¡ndez-Lobato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>SÃ¡nchez-Lengeling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Sheberla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Aguilera-Iparraguirre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.D.</ce:given-name>
                                 <ce:surname>Hirzel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.P.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aspuru-Guzik</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Automatic chemical design using a data-driven continuous representation of molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Cent. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>268</sb:first-page>
                              <sb:last-page>276</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">R. Gomez-Bombarelli, J.N. Wei, D. Duvenaud, J.M. Hernandez-Lobato, B. Sanchez-Lengeling, D. Sheberla, J. Aguilera-Iparraguirre, T.D. Hirzel, R.P. Adams, A. Aspuru-Guzik, Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules, ACS Cent. Sci. 4 (2018) 268-276.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Pereira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Caffarena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Dos Santos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Boosting docking-based virtual screening with deep learning</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J.Â Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2495</sb:first-page>
                              <sb:last-page>2506</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0350">J.C. Pereira, E.R. Caffarena, C.N. Dos Santos, Boosting Docking-Based Virtual Screening with Deep Learning, J. Chem. Inf. Model. 56 (2016) 2495-2506.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>